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1. ZUSAMMENFASSUNG 
 
Der „Signal Transducer and Activators of Transcription“ Stat3 vermittelt Signale von 
Cytokinen und Wachstumsfaktoren in den Zellkern und steuert fundamentale 
zellphysiologische Prozesse wie Proliferation, Differenzierung und Apoptose. Seit wenigen 
Jahren ist bekannt, dass Stat3 ein potenzielles Oncoprotein ist. Es tritt in konstitutiv aktiver 
Form in vielen malignen Tumoren auf und gilt heute als vielversprechende Zielstruktur zur 
Tumortherapie.  
In dieser Arbeitsgruppe wurde zum ersten Mal gefunden, dass Stat3 im colorectalen 
Carcinom (CRC) hyperaktiv ist.  Ziel dieser Arbeit ist es, Ursachen für die erhöhte Stat3 -
Aktivität und Auswirkungen von Stat3 auf die Malignität der Colon-Tumorzellen 
aufzuklären.  
Zur Verfügung standen mehrere CRC-Zelllinien, in denen verschiedenen Formen von 
Stat3 durch retrovirale Infektion  überexprimiert wurden. In dieser Arbeit wird gezeigt, 
dass eine verstärkte Expression von Stat3 in allen untersuchten Linien die Proliferation 
deutlich beschleunigt. Auch eine Aktivierung von Stat3 durch das Cytokin IL-6 führte zu 
einer schnelleren Zellteilung. Der proliferative Effekt war am stärksten, wenn eine 
konstitutiv aktive Mutante von Stat3 exprimiert wurde und wurde durch eine dominant-
negative Variante von Stat3 supprimiert. Der Einfluss von Stat3 auf die Zellproliferation 
ging einher mit der Tyrosinphosphorylierung des Proteins, die im Western-Blot untersucht 
wurde.  
Parallel dazu wurde der Einfluss von Stat3 auf Parameter der malignen Zelltransformation 
studiert. Eine konstitutiv aktive Mutante von Stat3 war in der Lage, sowohl die Entstehung 
von Kolonien in „Soft Agar“ zu induzieren als auch die Zellmigration durch künstliche 
Basalmembranen zu verstärken.  
Der zweite Teil der Arbeit widmet sich den Mechanismen, durch die Stat3 -Aktivität 
maligne Zelleigenschaften beeinflusst. Es wurde durch Verwendung von cDNA-Arrays 
und „Real Time RT-PCR“ gezeigt, dass in Tumorgewebe-Proben von CRC-Patienten die 
Expression der Matrix-Metalloproteinasen MMP-1, -3, -7 und -9 immer dann stark erhöht 
war, wenn gleichzeitig auch starke Stat3-Aktivierung zu beobachten war. Hieraus wurde 
die Hypothese abgeleitet, dass die Stat3 -Aktivität eine Ursache für die erhöhte Expression 
von Proteasen sein könnte, die dann das invasive Verhalten und damit die Malignität von 
Colorectal-Carcinomzellen fördern.  
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Die Untersuchungen konzentrierten sich auf die Matrix-Metalloproteinase MMP-1, in 
deren Promoterregion mehrere Erkennungssequenzen für STAT-Proteine identifiziert 
wurden. Für einen kausalen Zusammenhang zwischen Stat3 -Aktivität und MMP-1 
Expression sprach der immunhistochemische Nachweis der Kolokalisation in 
Tumorgewebe. Reportergenexperimente in CRC-Zelllinien erbrachten den Beweis einer 
spezifische Induktion des MMP-1 Promoters durch Stat3-Aktivität. Des weiteren wurde 
auch demonstriert, dass die erhöhte Produktion der MMP-1 mRNA durch Stat3 -
Vermittlung auch zu einer verstärkten MMP-1 Enzymaktivität führt.  
In dieser Arbeitsgruppe wurde zuvor gezeigt, dass die konstitutive Stat3 -Aktivität in CRC-
Zellen bei Kultivierung in vitro verloren geht. Interessanterweise kehrt sie zurück, wenn 
diese Zelllinien in Nacktmäuse implantiert werden und dort zu Tumoren auswachsen. Der 
letzte Teil dieser Arbeit umfasst Experimente zur Erklärung dieses Phänomen. Es wurde 
versucht, die Situation der Zellen im Tumor in Zellkultur nachzuahmen. Hierzu wurden die 
Zellen in nicht beschichteten Plastikgefäßen zu kultiviert, in denen sie nicht geordnet und 
adhärent wachsen, sondern unorganisierte Zellaggregate bilden. Es wurde gezeigt, dass 
unter solchen „tumorartigen“ Bedingungen Stat3 in den HT-29 Zellen durch Vermittlung 
eines sezernierten autokrinen Faktors aktiviert wird, bei dem es sich möglicherweise um 
ein Chemokin handelt. 
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2. SUMMARY 
 
Signal Transducer and Activator of Transcription Stat3 is a regulator of fundamental 
cellular processes such as proliferation, differentiation and cell death. It possesses 
oncogenic properties and was found aberrantly active in various malignant tumors. Target 
genes of Stat3 are important for survival, proliferation, inflammation and migration. It was 
recently shown that Stat3 is persistently active in the great majority of malignant colorectal 
tumors (colorectal carcinoma, CRC). However, its role in development and progression of 
this disease has not been investigated so far.  
One major purpose of this work is an analysis of functions of Stat3-activation in colorectal 
cancer cells by studying its influence on parameters such as cell proliferation, invasion 
properties, and anchorage-independent growth. Moreover, the project intends to correlate 
the expression of malignancy-associated proteinases with aberrant Stat3 activity, thereby 
possibly identifying novel target genes of Stat3 in the context of CRC. Another goal of this 
work is to investigate potential origins of persistent Stat3 activation in colorectal cancer 
tissue. Methods of discriminating between paracrine and autocrine mechanisms of Stat3 
are to be developed with the goal of obtaining information on the nature of the factor(s) 
that induce Stat3 activity in CRC cells. 
The potential functional involvement of Stat3 in the malignant transformation of colon 
epithelium cells was studied by using variants of the established colon carcinoma cell line 
HT-29 stably expressing different derivatives of Stat3. Heterologous overexpression of 
Stat3 and activation via the interleukin-6 resulted in accelerated cell proliferation, 
enhanced colony formation in soft agar and elevated invasiveness in vitro. All these effects 
were pronounced upon transfection with a constitutively active Stat3 mutant and 
suppressed by a dominant negative Stat3 variant. 
An important determinant of cancer cell malignancy, invasiveness and metastasis is the 
proteolytic degradation of different components of the extracellular matrix, such as 
basement membrane and interstitial stroma. Stat3 is known to be activated by various 
proteins that also influence protease expression. Therefore possible connections between 
the transcriptional regulation of various proteases and the activity of Stat3 in colon cancer 
cells were investigated.  
mRNAs from cancer samples were analyzed by means of cDNA arrays  and Real-Time 
RT-PCR for protease expression patterns. A striking correlation of strong Stat3 activity 
with upregulation of matrix metalloproteinases MMP-1, MMP-3, MMP-7 and MMP-9 was 
observed. Notably, Stat3 was able to positively regulate transcription from the MMP-1 
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promoter in colon carcinoma cell lines as shown by luciferase reporter gene experiments. 
Moreover, Stat3 promoted the secretion of enzymatically active MMP-1. Finally, the co-
localization of activated Stat3 and MMP-1 in tumor tissue could be demonstrated by 
immuno-histochemistry. 
Previously. constitutive Stat3 activity was found abundant in de-differentiated cancer cells 
of CRC samples, but not in non-neoplastic colon epithelium. Unexpectedly, cell lines 
derived from malignant colorectal tumors lost persistent Stat3 activity in culture. Earlier 
work from this laboratory showed that xenograft tumors arising from implantation of colon 
carcinoma cells into nude mice developed restoration of Stat3 activity. In this work, 
evidence was obtained for the involvement of an extracellular stimulus within the tumor 
microenvironment as a trigger for STAT activation. Growth conditions forcing detachment 
of CRC cancer cells induced the secretion of a Stat3-activating autocrine factor whose 
abundance correlated with the level of Stat3 phosphorylation, as shown by Western blot 
experiment. Preliminary results suggest that the autocrine activity has the nature of a 
chemokine. 
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 3. INTRODUCTION 
 
3.1. Significance and Causes of Colorectal Carcinoma  
 
3.1.1. Epidemiology and Prognosis of CRC 
Colorectal carcinoma (CRC) is the most common malignant tumor of the alimentary tract 
in the Western world; it is the second most common type of cancer death for both sexes in 
Germany. In men, CRC ranks third after lung and prostate carcinoma with 14.2%, in 
women it has the second position behind the mamma carcinoma with 16.8%. Incidence 
grows exponentially with age, with 90% of colorectal carcinomas appearing after the age 
of 50. In Germany alone, 50,000 new cases of CRC are diagnosed annually, and about 
50% of the patients die of the disease within 5 years. The incidence of CRC is considerably 
lower in Asia, Africa and South America (Klein et al., 2003). 
Sixty percent of the colorectal carcinomas are localized in the rectum, with 80% of these 
involving the rectum and sigma. At the time of diagnosis, colorectal carcinoma usually 
shows extensive local invasion and metastasis (Liotta, 1986). Prognosis of CRC depends 
on whether the tumor can be removed surgically. In the case of curative resection the 
prospects for the successful treatment of colorectal cancer depend critically on the stage at 
which the disease is diagnosed. The relative 5-year survival rates for colorectal cancer are: 
Stage Union Internationale Contre le Cancer - International Union Against Cancer (UICC) 
I: 90-100%; Stage UICC II: 78%; Stage UICC III: 54%, Stage UICC IV: 6%. Other than 
tumor stage, venous invasion, lymphogenic invasion and surgical quality are additional 
prognostic factors (Klein et al., 2003). 
The aetiology of CRC is not precisely defined, but involves a wide range of risk factors. 
Nutrition and life habits are believed to be of major relevance to the occurrence of 
gastrointestinal tumors. However, about 15% of colon and rectum carcinomas originate 
from genetic predisposition (Schackert et al., 1998). These genetically determined tumors 
include several syndromes that can be clinically and molecularly distinguished. 
 
3.1.2. Molecular Aspects of CRC Formation 
Colorectal tumors based on hereditary factors show a familial pattern of occurrence. 
Carriers of the very rare familial adenomatous polyposis (FAP) develop dozens or perhaps 
hundreds of intestinal polyps that, if untreated, progress to cancer in 60%-70% of cases. 
Most genetically determined bowel malignancies fall under the category of “hereditary 
INTRODUCTION                                                                                                                         12 
non-polypous colorectal cancer” (HNPCC). In this disease, also known as “Lynch 
syndrome”, intestinal tumors develop at a young age, usually in the right colon, and are 
commonly associated with multiple neoplasms in other organs (e.g., stomach, skin, uterus) 
(Ponz de Leon, 1994; Lynch et al., 1995). 
For research, both FAP and HNPCC syndromes represent models of carcinogenesis also 
for sporadic colorectal carcinomas. In this context, FAP is considered an equivalent of the 
more frequent (85%) “tumor suppressor” phenotype, whereas HNPCC mirrors the less 
frequent “mutator” phenotype (Reviewed in Reinacher-Schick and Schmiegel, 2002 ). 
Fundamental to the tumor suppressor phenotype is a multi-step accumulation of 
chromosomal and genomic aberrations and the development of a deoxyribonucleic acid 
(DNA) aneuploidy. It is associated with stepwise changes in phenotype, which represent 
the „classical“ adenom carcinom sequence. This process involves both oncogenes and 
tumor suppressor genes (Vogelstein and Kinzler, 2004).  
Activation of protooncogenes to yield oncogenes can happen through mutation, 
amplification or rearrangement. For gastrointestinal malignancies, multiple genetic 
aberrations have been described which basically concern the following groups: Oncogene-
encoding receptor tyrosine kinases (e.g., c-erbB-2), growth factors and their receptors (e.g., 
EGF receptor, cripto), mediators of intracellular signal transduction (e.g., K-ras, H-ras, N-
ras, c-Src), cell cycle regulators (e.g., pic-1), and transcription factors (e.g., c-fos and c-
jun). An additional issue is the phenomenon of genetic instability (Reviewed in Allgayer et 
al., 2001). Functional impairment of tumor suppressor genes results from mutations or loss 
of alleles. Important tumor suppressors in colorectal carcinogenesis are APC, genes on 
chromosome 18q (dcc, smad4 und smad2) and p53.  
c-erbB-2 is probably of prognostic value for gastrointestinal carcinoma. It codes for a 
transmembrane tyrosine kinase of 185 kD in size, and over-expression was found to be 
associated with an unfavourable prognosis (Tsugawa et al., 1998; Lee et al., 2002). 
Malfunction of intracellular signal transduction regulating has been associated with 
erroneous cell proliferation and differentiation. Here, much attention has been focused on 
the ras oncogenes (N-ras, K-ras, H-ras). They encode G-proteins localized at the 
intracellular face of the plasma membrane which transmit proliferative signals emanating 
preferentially from receptor tyrosine kinases. Mutations within in ras genes can lead to an 
elimination of the Ras proteins’ intrinsic GTPase activity, resulting in a state of persistent 
activation (e.g., Yan et al., 2002; Johnson et al., 2003). In gastrointestinal cancers, ras 
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mutations are most frequently found in carcinomas of the colon, rectum and pancreas. C-
ras is discussed as a potential prognostic factor in CRC (Tsuda et al., 1995). 
Elevated activity of the non-receptor tyrosine kinase Src in colon carcinoma compared to 
normal mucosa was reported in various studies (e.g., Aligayer et al., 2002). Src is involved 
in cell proliferation, rearrangement of the cytoskeleton and cell transformation. Aberrant 
activation can be caused by mutations, but is mainly the result of de-regulation of upstream 
signal cascades. Recent investigations point to an association of Src activity with enhanced 
invasiveness in colon carcinoma (Pories et al., 1998). 
With regard to tumor suppressors, many clinical studies have centered around the role of 
p53. The wild-type form of this multifunctional protein induces negative regulators of the 
cell cycle such as Pic1, p21 and p27, and leads to an arrest in the G1 phase. After 
irreparable DNA damage, it leads to apoptosis, thus protecting the organism against 
malignantly transformed cells. These functions are impaired in p53 mutants associated 
with malignant tumors (Shiohara et al., 1994). In colon carcinoma, p53 malfunction is 
related to lymph node metastasis and shortened survival (Campo et al., 1994; Hamelin et 
al., 1994; Gervaz et al., 2002). 
The tumor suppressor gene nm23 encodes a nucleotide diphosphate kinase and is involved 
in the suppression of tumor occurrence and metastasis (Boyd, 1989). Reduced expression 
of nm23 in colon carcinoma appears to be associated with the development of lymph node 
metastases (Brenner et al., 2003). It also seems to be of prognostic value in CRC (Bertucci 
et al., 2004). 
Bcl-2 encodes an anti-apoptotic protein associated with the mitochondrial membrane. 
Ayhan et al. (1994) observed frequent loss of heterocygocity (LOH) of the bcl-2 locus in 
gastric carcinomas. 
Mutations in the APC (adenomatosis polyposis coli) gene are essential in colorectal 
carcinogenesis. Since they occur in an early stage of the “adenoma carcinoma sequence”, 
APC is believed to have a “gatekeeper” function. APC mutations influence catenin-
mediated gene regulation and lead to intra- and intercellular malfunctions (Reviewed in 
Karim et al., 2004). They can be detected in hyperproliferative colon mucosa prior to the 
occurrence of an adenoma; loss of the second APC allele usually happens in the early 
phase of adenoma development. Additional genetic alterations (K-ras, p53) subsequently 
result in the stepwise progression towards carcinoma formation (Heinzlmann et al., 2001). 
The “mutator” phenotype is associated with defects in DNA repair processes. In the course 
of carcinogenesis, mutations or (inactivating) promoter hypermethylation in mismatch 
INTRODUCTION                                                                                                                         14 
repair genes cause multiple mutations in genes that directly or indirectly influence cell 
transformation, such as those encoding the receptor for transforming growth factor (TGF)-
β or the anti-apoptotic protein Bax (Schalhorn et al., 2001). In hereditary non-polypous 
colon carcinomas (HNPCC), four different mismatch repair genes have been identified 
(hMLH1, hMSH2, hMSH6, PMS2) in which mutations are causal for malignant 
transformation (Liu et al., 2003; de Jong et al. 2004). Impaired DNA replication results in 
DNA microsatellite instability (MSI), the presence of repetitive mono-, di-, tri- or 
tetranucleotide sequences (Parker et al., 2004). However, MSI is not specific for HNPCC, 
but is also observed in 15% of sporadic tumors (Vogelsang et al., 2001).  
Altogether, carcinogenesis is a multistage process that involves multiple genetic and 
epigenetic events (Brown and Balmain, 1995; Balmain and Harris, 2000). These events are 
divided into three independent stages: initiation, transformation, and progression. The rate-
limiting events in multistage carcinogenesis are believed to occur during transformation 
and progression. Thus, identifying the specific signalling pathways in the rate-limiting step 
is important to prevent cell transformation, as well as to inhibit tumor growth. In recent 
years several novel potential tumor markers and targets for therapy have been identified. 
Among them, the STAT family of transcription factors received much attention. 
  
 
3.2. Stat3 in Tumor Formation 
  
3.1.1. The Stat Family of Transcription Factors 
Signal transducer and activator of transcription (STAT) proteins are a family of 
transcription factors that transmit signals, usually generated at cell surface receptors, to the 
nucleus where STATs bind to specific DNA promoter sequences, thereby regulating gene 
expression. Since discovery of the first STATs as key mediators of IFN signalling, a total 
of seven different STAT family members (Stat1, Stat2, Stat3, Stat4, Stat5A, Stat5B, and 
Stat6) encoded in distinct genes have been identified in mammalian cells (Darnell, 1997). 
STATs are normally inactive within the cytoplasm of cells and become activated by 
tyrosine phosphorylation in response to cytokines and growth factors. Signalling pathways 
mediated by STATs are critical for many normal cellular functions, including embryonic 
development, organogenesis, immunological interaction, growth, differentiation and 
survival (Buettner et al., 2002). In summary, Stat1-deficient mice are unable to respond to 
IFNs and are subsequently susceptible to bacterial and viral pathogens. Likewise, 
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disruption of Stat2 gives rise to animals unable to respond to type 1 IFNs, with increased 
susceptibility to viral infections (Candotti et al., 2002). Stat4- and Stat6-deficient animals 
reveal a requirement for interleukin (IL)-12– or IL-4–mediated proliferation of T cells, 
respectively (Decker et al., 2002). The phenotypes of Stat5A and Stat5B individual 
knockout mice reveal the importance of Stat5A in breast development and lactation and the 
importance of Stat5B in the development of sexually dimorphic patterns of gene 
expression within the liver. In addition to these phenotypes, Stat5A/5B double knockout 
mice are abnormal in their T cell and B cell development. Because Stat3-deficient animals 
die early in embryogenesis, the role of this protein in a number of biological functions had 
to be determined in conditional knockouts (see 2.2.2.).  
The activation duration of STATs under physiological conditions is temporary and usually 
lasts anywhere from a few minutes (min) to several hours (h), and is tightly regulated by a 
number of cellular mechanisms such as tyrosine dephosphorylation, ubiquitin/ proteasome-
mediated degradation, a negative feedback loop mediated by the CIS/SOCS/JAB/SSI 
family of proteins, or inhibition of STAT DNA-binding activity through association with a 
protein inhibitor of activated STAT (PIAS) proteins (Reviewed in Lin and Leonard, 2000). 
However, constitutively activated STATs, especially Stat1, Stat3 and Stat5, have been 
found in a variety of human tumors and cancer cell lines (Tab. 1), including blood 
malignancies and solid tumors (Turkson and Jove, 2000). In various tumor cell lines, 
persistent signalling of specific STATs, in particular Stat3 and Stat5, has been shown to 
stimulate cell proliferation and prevent apoptosis through up-regulating a number of target 
genes encoding apoptosis inhibitors (Bcl-xL, Mcl-1), cell cycle regulators (cyclins D1/D2, 
c-Myc), and inducers of angiogenesis (Vascular Endothelial Growth Factor (VEGF)). Not 
surprisingly, inhibition of constitutively activated Stat3 or Stat5 leads to growth 
suppression or apoptosis. Although Stat1 activation is elevated in some tumors and cell 
lines, the function of this molecule has been associated with growth suppression rather than 
malignant transformation and thus can be considered a potential tumor suppressor 
(Buettner et al, 2002).  
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Tab. 1: STAT activation in human cancer cell lines and primary tumorsa 
 Activated STAT 
Blood tumors  
Multiple myeloma Stat1, Stat3 
Leukemias  
HTLV-I-dependent Stat3, Stat5 
Erythroleukemia Stat1, Stat5 
Acute lymphocytic leukemia Stat1, Stat5 
Chronic lymphocytic leukemia Stat1, Stat3 
Acute myelogenous leukemia Stat1, Stat3, Stat5 
Chronic myelogenous leukemia Stat5 
Megakaryotic leukemia Stat5 
Large granular lymphocyte leukemia Stat3 
Lymphomas  
EBV-related/Burkitt’s Stat3 
Mycosis fungoides Stat3 
HSV saimiri-dependent (T-cell) Stat3 
Cutaneous T-cell lymphoma Stat3 
Hodgkin’s disease Stat3 
Solid tumors  
Breast cancer Stat1, Stat3, Stat5 
Squamous cell carcinoma of the head 
and neck (SCCHN) Stat1, Stat3 
Renal cell carcinoma Stat3 
Melanoma Stat3 
Ovarian carcinoma Stat3 
Lung cancer Stat1, Stat3 
Prostate carcinoma Stat3 
Pancreatic cancer Stat3 
Brain tumors Stat1, Stat3 
                                              a Modified after Buettner et al., 2002 
 
The origins of STAT activation are diverse, both in healthy and tumor tissue. Many 
different polypeptides (cytokines, hormones, growth factors) can activate STAT proteins, 
either through kinases of the janus kinase (Jak) family, which associate with receptors that 
are devoid of tyrosine kinase activity (e.g., receptors of the glycoprotein (gp) 130 family), 
or by receptor tyrosine kinases carrying their own kinase domain (e.g., EGF-R, PDGF-R 
(Bowman et al., 2001), IGF-1R (Zong et al., 2000)). It has also been shown in several 
studies, that STAT proteins are activated by some non-receptor tyrosine kinases (e.g., v-
Src (Garcia et al., 2001)) or through G-protein-coupled receptors (macrophage 
inflammatory protein (MIP)-1, RANTES) (Tab. 2). Stat2, Stat4 and Stat6 are activated 
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primarily by one or two single extracellular factors, whereas Stat1, Stat3 and Stat5 can be 
activated by a wide variety of factors (Levy and Gilliland, 2000; Bromberg, 2001) or 
oncoproteins (Migone et al., 1995; Garcia and Jove, 1998). Stat1α, Stat5, and Stat6 are 
indirectly linked to the malignancy of fibroblasts that are transformed by oncoproteins 
(Garcia et al., 1997). Stat3 is required specifically for v-Src induced transformation (Yu et 
al., 1995; Bromberg et al., 1998; Turkson and Jove, 2000). However, unlike the other 
STATs, Stat3 can act as an oncoprotein by itself (Bromberg, et al. 1999).  
 
Tab. 2: Cytokines, growth factors and oncogenes that activate signal transducers and activators of 
transcription (STAT) proteins relevant for oncogenesisa 
 
Stat1 Stat3 Stat5 
IFNα, IFNγ 
EGF, PDGF, FGF 
c/v-Eyk 
ACRII 
IL-6, IL-11, OSM, CNTF, 
LIF, IL-10, GM-CSF, leptin
EGF, PDGF, v-Sis 
Insulin, TSH 
MIP-1, RANTES, MCP-1 
Galphao 
Npm-alk 
Gαo 
c-Met, Ret, Ros 
Middle T antigen 
c/v-Src, v-Eyk, v-Abl, v-Fps
c-Fes, Lck, Tel-Jak, Etk 
 
IL-2, IL-7, IL-9, IL-15, IL-3, 
IL-5, GM-CSF 
EGF 
v-Abl  
Growth hormone, prolactin, 
erythropoetin, thrombopoetin
 
IFN, interferon ; IL, interleukin; EGF, epidermal growth factor; PDGF, platelet-derived 
growth factor; CNTF, ciliary neurotrophic factor; LIF, leukaemia inhibitory factor; GM-
CSF, granulocyte-macrophage colony-stimulating factor; MIP-1, macrophage inflammatory 
protein; MCP-1, monocyte chemotactic protein-1; OSM, oncostatin M. 
a Modified after Bromberg, 2000 and Bromberg, 2001 
 
Dimerisation through reciprocal SH2-phospho-tyrosine interactions of tyrosine-
phosphorylated STATs can occur  either as homodimers, as seen with all STATs except 
Stat2, or in some cases as heterodimers, as seen with Stat1/2, Stat1/3, and Stat5A/5B. This 
leads to their accumulation in the nucleus where they interact with other transcriptional 
modulators bound to specific promoter sequences (cognate sequences of the type 
TTCNNNGAA) and directly regulate gene expression (Fig. 1). STAT dimers are 
dephosphorylated within the nucleus and transported back to the cytoplasm (Darnell, 1997). 
In normal cells, STAT activation is transient, whereas in a large number of primary tumors 
and cancer-derived cell lines, STAT proteins (in particular Stat3) remain activated by 
persistently activated tyrosine kinases and/or a decrease in the negative regulators of STAT 
dephosphorylation (Bromberg, 2002).  
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Fig. 1: A simplified overview of the STAT activation and function an 
example of the Stat3. STAT proteins become tyrosine-phosphorylated by 
at least four different mechanisms: (1) Cytokine-mediated activation of the 
Jaks (e.g., IL-6, IFN); (2) Receptor tyrosine kinase mediated activation 
(e.g., EGFR, PDGFR); (3) Non-receptor tyrosine kinase (Src, Abl, Ros) 
and (4) G-protein-mediated activation (chemokines, TSH). Two tyrosine 
phosphorylated STAT proteins form dimers, and translocate into the 
nucleus. Once in the nucleus, STAT dimers bind specific promoter 
sequences, regulating the transcription of target genes. 
 
The basic molecular topology of STAT proteins is illustrated in Fig. 2 using Stat3 as the 
prototype. The protein interaction site is required for dimer-dimer interactions to form 
tetrameric STAT molecules. Tetramerisation of STATs contributes to stabilized DNA-
binding activity on weak promoters (John et al., 1999). The adjacent coiled-coil domain is 
another protein-protein interaction site that provides potential contacts for transcription 
factors and other regulatory proteins (Bromberg and Darnell, 2000). The DNA-binding 
domain in the center of the molecule determines DNA sequence specificity of individual 
STATs (Becker et al., 1998). A linker region that participates in DNA-binding leads to the 
COOH-terminal SH2 domain, which is required for the recruitment of STATs to 
phosphorylated receptors and for reciprocal SH2-phosphotyrosine interactions between 
monomeric STATs to form dimers (Shuai et al., 1994). The critical tyrosine (Y) residue 
required for SH2-phosphotyrosine interaction and thus STAT activation is located near the 
SH2 domain. 
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Fig. 2: The domain structure of full-length STAT proteins illustrated using Stat3 as the 
prototype. Color scheme: Y, critical phosphotyrosine (amino acid 705); S, critical phosphoserine 
(amino acid 727); TAD, transactivation domain. See text for more details on the STAT functional 
domains.  
 
 
The transactivation domain (TAD) at the COOH-terminal end of the molecule is involved 
in communication with transcription complexes and, in case of Stat1 and Stat3, contains a 
serine (S) phosphorylation site (Wen et al., 1995). Serine phosphorylation has been shown 
to be required for maximal transcriptional activation of STATs. The primary amino acid 
sequence of the TAD varies between individual STATs but is essential for STAT function 
as shown by deletion experiments. Cell lines mutated in the critical residue in Stat1 retain 
only 20% of the activity of the wild-type Stat1 and are defective in response to interferon 
(IFN). TAD-deficient STATs still bind to DNA but usually function as dominant-negative 
counterparts of the full-length forms (Buettner et al., 2002). Such truncated forms, for 
example Stat3-β (Caldenhoven et al., 1996), have been identified as naturally-occurring 
splice variants, but their normal physiological functions are not yet clear. Dominant-
negative STATs, as well as activated mutants of STATs (such as “Stat3 c.a.”, which is 
constitutively activated by forced dimerisation) (Bromberg et al., 1999), have been used to 
unravel the role of STATs in malignant transformation. Candidate serine kinases for the 
phosphorylation of STATs include the various mitogen-activated protein kinase family 
members (Turkson et al., 1999; Decker and Kovarik, 2000). The significance of STAT 
serine phosphorylation is not completely understood. However, the discovery that STATs 
cross-talk with members of other pathways, such as mitogen-activated protein kinase, 
indicates that STATs are embedded in complex signalling networks. 
Besides serine kinases, many other (co)activators of STAT signalling have been identified 
thus far, including the histone acetyl transferases p300/CBP (E1A-binding protein 300), 
the transcription factors c-Jun, Sp1, and glucocorticoid receptor, the coactivators Nmi (N-
Myc interactor) and MCM (minichromosome maintenance), the nuclear translocation 
protein NPI-1 (nucleoprotein interactor-1), and p48 (IFN regulatory factor family protein ) 
(Bromberg and Darnell, 2000; Shuai, 2001). The physiological importance of the above-
mentioned modulators of STAT signalling remains to be determined.  
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3.1.2. Roles of Stat3 in Oncogenesis 
Stat3 is a SH2 domain-containing transcription factor that is latent in the cytoplasm of cells 
until stimulation with cytokines, growth factors and oncogenic tyrosine kinases with a 
pattern of cell-type dependence (e.g., Sadowski et al., 1993; Johnston et al., 1995; Stancato 
et al., 1996; Takeda et al., 1998) (see Tab. 2). Stat3 was discovered in 1994 by three 
independent groups as an acute-phase response factor produced by liver cells (Lütticken et 
al., 1994; Akira et al., 1994) or by cloning from a murine cDNA bank (Zhong et al., 1994), 
and named Stat3 by Zhong and co-workers. Three main Stat3 isoforms have been 
described: Stat3-α with 92kDa, the shorter splice isoform Stat3-β of 83kDa and Stat3-γ, a 
short 72 kDa isoform of unknown physiological function, which is generated through 
proteolytic cleavage of Stat3-α (Akira et al., 1994; Hevehan et al., 2002).  
Targeted disruption of Stat3 revealed that it is essential for early embryonic development, 
because mice lacking Stat3 die before birth (Takeda et al., 1997). Tissue-specific gene 
deletions have demonstrated a critical role of Stat3 in the regulation of epithelial cell 
apoptosis, involution in the post-lactating mammary gland, skin remodelling, keratinocyte 
migration, macrophage inactivation, and down-regulation of inflammatory cytokines in T-
helper cell responses (Chapman et al., 1999; Sano et al., 1999; Takeda et al., 1999). 
Furthermore, many different studies investigating STAT signalling (using established cell 
lines, primary cell cultures, and animal models as well as clinical tumor samples with 
matched adjacent normal tissues) suggest that Stat3 is highly activated in many types of 
cancer cells (e.g.,Garcia et al., 1997; Bromberg et al., 1999; Bowman et al., 2000), and 
constitutively activated Stat3 actively participates in tumor development and progression 
(see Tab. 1) (e.g.,Catlett-Falcone et al., 1999; Bromberg and Darnell, 2000; Turkson and 
Jove, 2000; Bowman et al., 2000; Chan et al., 2004; Nakanishi et al., 2004).  
A critical role for Stat3 in malignant transformation was first proposed after initial studies 
showed that Stat3 is constitutively activated during v-Src transformation (Yu et al., 1995). 
More recent studies have confirmed this view and have demonstrated that Stat3 signalling 
is required for oncogenic transformation by v-Src (Bromberg et al., 1998; Turkson et al., 
1998). In addition to v-Src, many other transforming tyrosine kinases, such as v-Eyk (east 
lansing tyrosine kinase), v-Ros (viral Ros), v-Fps (Fujinami avian sarcoma viral oncogene 
(v-Fes)), Etk/BMX (epithelial and endothelial tyrosine kinase), and Lck (lymphocyte-
specific protein-tyrosine kinase), constitutively activate Stat3 in the context of oncogenesis 
(Bowman et al., 2000). Genetic evidence for the intrinsic oncogenic potential of Stat3 
derives from an experimentally designed constitutively active mutant of Stat3. The “Stat3 
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c.a.” protein is sufficient for mediating certain aspects of cellular transformation of rodent 
fibroblast cells when stably expressed, and cells transformed by “Stat3 c.a.” have the 
ability to form tumors in nude mice (Bromberg et al., 1999). Blocking of Stat3 DNA 
binding with antisense oligonucleotides or a dominant-negative Stat3 protein, Stat3-β, 
further established the critical role of Stat3 in oncogenesis (Reviewed in Bowman et al., 
2000; Song and Grandis, 2000). In all cases, inhibition of persistent Stat3 signalling 
suppressed the transformed phenotype. In several cases, Stat3 was not shown to be 
essential for viability of normal cells (Ebong et al., 2004). In contrast, many cancer-
derived cell lines that contain constitutively activated Stat3 are dependent on this. 
Introduction of dominant negative Stat3 or Stat3 antisense oligonucelotides leads to 
induction of apoptosis, decreased angiogenesis, or growth arrest of these cells (Akira, 
2000; Garcia et al., 2001; Bromberg, 2002). 
Because many different cytokines are known to activate STATs (Ihle, 2001), it is not 
surprising that constitutive activation of Stat3 is observed downstream of aberrant 
cytokine signalling derived from either autocrine or paracrine sources. In the context of 
cytokines, IL-6 signaling through the gp130 receptor subunit is particularly relevant in 
multiple myeloma and prostate cancer because IL-6-mediated activation of Stat3 has a key 
role in preventing apoptosis and stimulating growth in cancer cells derived from these 
tumors. Stat3 activation is also linked to a number of receptors with intrinsic tyrosine 
kinase activities that are independent of the cytokine receptor gp130 subunit (Buettner et 
al., 2002). With regard to growth factor receptor signalling, the role of Stat3 in 
oncogenesis is well investigated in squamous cell carcinoma of the head and neck 
(SCCHN) and breast cancer. Human SCCHN cells, but not normal mucosal epithelial 
cells, typically over-express both the TGF-α and its cognate receptor, EGF receptor (Song 
and Grandis, 2000). It has been demonstrated that TGF-α /EGF receptor-mediated growth 
of transformed epithelial cells is dependent on the activation of Stat3.  
 
Cellular transformation by activated Stat3 and its relatives occurs through the 
transcriptional regulation of specific genes. Many Stat3 target genes are known, including 
antiapoptotic proteins, proliferation-associated proteins, and proangiogenic factors (Tab. 
3). Still other genes must be regulated indirectly by Stat3, as shown by cDNA array 
studies, many of which may contribute to oncogenesis or tumor progression, e.g., flotillin, 
phospholipid scramblase 1, caveolin-2, growth arrest specific-6 (Gas 6), CD-44, 
osteopontin and PDGF (Brocke-Heidrich et al., 2004). 
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Tab. 3: Stat3 target genes 
Stat3 target 
gene 
Reference 
fra-1 Zerbini et al., 2003 
fra-2 Rydziel et al., 2000 
c-fos e.g., Ruff-Jamison et al., 1994; Servirei et al., 1998 
c-jun e.g., Fujitani et al., 1994; Zhang et al., 1999 
c-myc e.g. ,Yamanaka et al., 1996; Narimatsu et al., 1997; Bowman et al., 
2001 
c-myb e.g., Yamanaka et al., 1996; Minami et al., 1996; Narimatsu et al., 
1997 
fos-B Rydziel et al., 2000 
fas (together 
with c-jun) e.g., Catlett-Falcone et al., 1999; Ivanov, 2001 
bcl-2 e.g., Fukada et al., 1996; Epling-Burnette et al., 2001 ; Brocce-Heidrich et al., 2004 
bcl xl e.g., Zushi et al., 1998; Alas and Bonavida, 2003 
mcl-1 e.g., Puthier et al., 1999; Epling-Burnette et al., 2001 
E-cadherin e.g., Rivat et al., 2004 
SOCS-3 e.g., Starr et al., 1997 
PIAS-3 Russell and Richards, 1999 
VEGF e.g., Niu et al., 2002; Wei et al., 2003 
pim-1 Demoulin et al., 1999; Narimatsu et al., 2001 
pim-2 Shirogane et al., 1999 
cyclin D1 e.g., Cressman et al., 1996 
ICAM-1 e.g., Caldenhoven et al., 1996; Romano et al., 1997 
CD-18 e.g., Wooten et al., 2000;  
jun B e.g., Yamanaka et al., 1996;Rydziel et al., 2000 
jun D e.g. Zerbini et al., 2003; Rydziel et al., 2000 
β-catenin e.g. Yamashita et al., 2002; Uttamsingh et al., 2003 
p19/ink4d e.g. Tanaka et al., 2000; Demoulin et al., 2001 
α (M) integrin Panopoulos et al., 2002 
β (2) integrin Panopoulos et al., 2002 
β-actin Naruishi et al., 2001; Efferth et al., 2000 
VLA-5 (α5 β1 
integrin) Naruishi et al., 2001 
p 27/kip1 e.g., Kortylewski et al., 1999; Wooten et al., 2000 
α 1-antychymo- 
trypsin (pACT) Terstegen et al., 2001 
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 3.2. Cell Invasiveness, a Major Parameter of Malignancy in 
CRC  
 
3.2.1. Acquisition of Invasive Properties by Carcinoma Cells 
Metastatic spread of tumor cells is one of the major risk factors affecting clinical 
prognosis. Cancer cells possess a broad spectrum of migration and invasion mechanisms. 
These include both individual and collective cell-migration strategies. 
As tumors become increasingly malignant, cells within them develop the ability to invade 
into surrounding normal tissues and through tissue boundaries to form daughter neoplasias 
(metastases) at sites distinct from the primary tumor. There are several sequential steps in 
this process including cell migration into the surrounding host tissue, infiltration and 
penetration into vessels for dissemination, attachment to capillary beds of distant organs, 
cell extravasation and subsequent growth in tissues. Invasion and metastasis are not unique 
for cancer as they also occur during embryonic development  and in many non-cancerous 
diseases, such as ectodermal cell invasion during mesoderm formation, migration of neural 
crest cells and leukocyte motility (Le Douarin, 1993; Springer, 1994; Thier, 2002). Thus, 
the so-called cell migration genes may be frequently utilized by cancer cells to allow for 
metastatic spread of disease. Highly invasive cancers are usually characterized by aberrant 
activity of specific intra- or extracellular molecules such as protein kinases, phosphatases, 
transcriptional factors, proteolytic enzymes, and others (Reviewed in Sliva, 2004). 
Tumor invasion can be considered as a process in which cells are activated, then move 
away from their initial location, by modifying their adhesiveness to the extracellular 
matrix, expressing new adhesion molecules and degrading the extracellular matrix 
components by the active secretion of proteases. These events require complex cross-
talking between endothelial and tumor cells, extracellular matrix components, and cellular 
elements of the microenvironment. Adhesion molecules, such as integrins and cadherins, 
play a major role in signalling from outside to inside a cell, thereby controlling a cell’s 
ability to sense and interact with its local environment (Allgayer et al., 1997; Perl et al., 
1998). In the case of gastrointestinal carcinoma, E-cadherin, CD-44 (Cluster Designation-
44) and ICAM-1 (Intracellular Adhesion Molecule 1) have been shown to be important for 
invasiveness (de Both et al., 1999; Alexiou et al., 2001; Masaki et al., 2001). 
Importantly, proteolytic enzymes and their inhibitors (e.g., matrix metalloproteinases and 
TIMPs) not only have the ability to break down the components of the extracellular matrix, 
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but are also involved in the release of factors which can positively or negatively affect the 
growth of the tumor cells (e.g., Schwartz et al., 1994; Heiss et al., 1995; Cairns et al., 
2003). Both processes are under the tight regulation of a balance between stimulating and 
inhibiting factors. The existence of common mechanisms of regulation and the presence of 
naturally-occurring factors that inhibit invasion make the inhibition of both processes 
possible. Tumor cells may develop adaptive mechanisms that enable the tumor to 
withstand the treatment, particularly when only one mechanism or one process is inhibited.  
In post-extravasational stages of metastasis, the roles of adhesion and proteolysis are 
accompanied by other processes such as apoptosis, dormancy, growth factor-receptor 
interactions and signal transduction. Recent work has also demonstrated that not only the 
immediate cellular microenvironment (i.e., specific cell-cell and cell-matrix interactions), 
but also the extended cellular microenvironment (i.e., vascular insufficiency and hypoxia in 
the primary tumor), can modify cellular gene expression and enhance metastasis 
(Reviewed in Cairns et al., 2003). Mechanisms of invasiveness and metastasis also involve 
a transcription deregulation of proto-oncogenes, such as c-Met. The c-Met protein contains 
a tyrosine kinase domain that initiates a range of signals to regulate various cellular 
functions (Bottaro et al., 1991). Hepatocyte growth factor (HGF)/scatter factor (SF) 
produced by stromal fibroblasts acts in a paracrine manner on cancer cells via the c-Met 
receptor (Trusolino et al., 2002). The activation of this receptor can induce proliferation, 
motility, adhesion, and invasion in tumor cells (e.g., Jiang et al., 1993; Uchiyama et al., 
1996). Over-expression of c-Met protein has been correlated with tumor progression and 
prognosis in breast cancer, gastric cancer, hepatocellular, endometrial, and nasopharyngeal 
carcinomas (Kuniyasu et al. 1993; Ueki et al., 1997; Ghoussoub et al., 1998; Wagatsuma 
et al., 1998; Qian et al., 2002). c-Met has been suggested to be associated with colorectal 
cancer (CRC) progression (Trusolino et al., 2002). Bilchik et al. (2001) reported on the 
utility of c-Met as an RT-PCR marker for detecting micrometastasis of CRC in sentinel 
lymph nodes. Takeuchi et al. hypothesized that over-expression of c-Met mRNA in 
primary CRC can predict tumor invasion and regional metastasis. Interestingly, Stat3 is 
one of the mediators activated by c-Met and is involved in c-Met-induced cell motility 
(Boccaccio et al., 1998). 
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 3.2.2. Role of Tumor Associated Proteases und Protease Inhibitors in 
Invasiveness of Gastrointestinal Carcinoma Cells 
Matrix degradation in the course of invasive growth is mediated by the concerted action of 
several proteinases, including members of the serine, cysteine, aspartate, and MMP 
families (Brinckerhoff et al., 2000). It is well established that various proteases are 
frequently over-expressed in tumors, and that tumors with strong protease expression are 
often more aggressive than those with lower expression levels. 
This is evident for the urokinase type-plasminogen activator (uPA) system, which consists 
of the 55 kDa serine protease uPA, its membrane-bound receptor uPA-R, and the specific 
inhibitors plasminogen activator (PAI)-1 and -2. uPA activates plasminogen to form 
plasmin, resulting in the degradation of surrounding matrix elements and simultaneous 
activation of collagen, which in turn degrades basal membranes. The inhibitors and PAI-1 
are essential for the transcellular recirculation of uPA-R, thereby guaranteeing a dynamic 
and flexible proteolytic system at the surface of tumor cells. Moreover, PAIs are 
speculated to protect inner tumor segments from self-destruction by excess proteolysis and 
to induce neo-angiogenesis of newly established metastases (Boyd, 1989; Schmitt et al., 
1992; Nekarda et al., 1994; Schwartz et al., 1994; Heiss et al., 1995). The urokinase-
receptor (u-PAR) promotes plasminogen-dependent extracellular matrix degradation in 
gastric or colon cancer. Over-expression of u-PAR has been reported to occur mainly at 
the transcriptional level in malignant cells, and has been shown to indicate a poor clinical 
prognosis of cancer patients. (Reviewed in Allgayer, 2003).  
The majority of connective tissue destruction is carried out by the Matrix-
Metalloproteinases (MMPs), a family of zinc-dependent enzymes that degrades all 
components of connective tissues. Currently, 26 human MMPs have been identified, and 
these enzymes are classified according to their substrate specificity and structural 
similarities. There are four major subgroups: (a) interstitial collagenases; (b) gelatinases; 
(c) stromelysins; and (d) MT-MMPs. The interstitial collagenases degrade structural 
collagens types I, II, and III, which is followed by further breakdown by gelatinases and 
stromelysins.  
The gelatinases are effective primarily against type IV collagen, although a limited ability 
to degrade stromal collagens has been noted. The stromelysins have broad substrate 
specificity, degrading non-collagen matrix molecules, such as proteoglycans, laminin, and 
fibronectin, but they indirectly mediate collagen degradation by contributing to the 
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activation of other latent MMP family members. The MT-MMPs represent membrane-
bound forms of the enzymes, which activate latent MMP-2 and which can cleave collagen 
at the classic site (Parsons et al., 1997; Curran and Murray, 1999; Nagase and Woessner, 
1999; Velesco et al., 2000). 
MMP expression is low in most normal cells under physiological conditions. In normal 
tissues, they are thought to play a major role in tissue growth and remodelling (Behera et 
al., 2004); however, MMP expression is dramatically increased in a variety of cancer 
types, where it is indicative of invasive disease with a poor clinical prognosis (Airola et al., 
1999; Walker et al., 1999; Hofmann et al., 2000; Nikkola et al., 2002). Specific 
mechanisms exist, by which individual matrix metalloproteinases, especially membrane-
type matrix metalloproteinases, interact with cell adhesion molecules and cytoskeletal 
proteins, thus dynamically contributing to colorectal tumor invasion (Leeman et al., 2003). 
For example, matrilysin (MMP-7) is activated at an early stage of colorectal 
tumourigenesis by the β-catenin signalling pathway. A particularly important member of 
the MMP family is the interstitial collagenase MMP-1, which degrades the most abundant 
proteins of the extracellular matrix (collagen types I and III). MMP-1 levels increase 
during colorectal carcinoma progression (Baker et al., 2000; Yamashita et al., 2001;) 
where they are associated with shorter disease-free survival (Murray et al., 1998; Shiozawa 
et al., 2000). In in vitro assays, this increase was necessary to induce colon carcinoma cell 
invasion through a synthetic extracellular matrix (ECM). Aberrant expression of MMPs 
has also been documented in head and neck carcinomas, astrogliomas, gastric cancer, and 
melanomas (Reviewed in Curran and Murray, 1999).  
Several recent studies addressed signalling pathways which are regulated in colorectal 
cancer development. The expression of MMPs is greatly modulated by cytokines and 
growth factors, which induce cellular responses by activating intracellular signalling 
cascades including the mitogen-activated protein (MAP) kinase via specific cell surface 
receptors (e.g., Korzus et al., 1997; Yu et al., 2002; Udayakumar et al., 2003). Among the 
nuclear substrates of MAP kinase, some were found that are directly involved in MMPs 
transcriptional regulation. These include the gene products of fos and jun oncogenes which 
compose the activator protein-1 (AP-1) transcription factor, as well as ets family members, 
for example extracellular signal-regulated kinases (Erk) 1/2 site in the MMP-1 promoter 
(e.g., Curran et al., 1999; Brinckerhoff et al., 2000; Horiuchi et al., 2003; Tower et al., 
2003; Huntington et al., 2004). Interstitial collagenase 1 (MMP-1) and tissue inhibitor of 
metalloproteinases 1 (TIMP-1) genes are co-ordinately up-regulated by growth factors as 
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well as by several nuclear and non-nuclear oncogenes. This can be explained by the 
combined actions of transcription factors operating through composite ets/Ap-1 motifs in 
some mammalian promoters, including MMP-1 and TIMP-1 (Korzus et al., 1997).  
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 4. STUDY OBJECTIVE 
A very interesting emerging target in cancer therapy is the signal transducer and activator 
of transcription - 3 (Stat3). It was recently shown that Stat3 is persistently active in the 
great majority of malignant colorectal tumors (colorectal carcinoma, CRC). However, its 
role in development and progression of this disease has not been investigated so far.  
One major purpose of this work is an analysis of functions of Stat3-activation in colorectal 
cancer cells, by studying its influence on parameters such as cell proliferation, invasion 
properties, and anchorage-independent growth. Moreover, the project intends to correlate 
the expression of malignancy-associated proteinases with aberrant Stat3 activity, thereby 
possibly identifying novel target genes of Stat3 in the context of CRC. 
Another goal of this work is to investigate potential origins of persistent Stat3 activation in 
colorectal cancer tissue. Methods of discriminating between paracrine and autocrine 
mechanisms of Stat3 are to be developed with the goal of obtaining information on the 
nature of the factor(s) that induce Stat3 activity in CRC cells. 
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 5. MATERIALS AND METHODS 
 
5.1. Materials 
 
5.1.1. Biological materials 
5.1.1.1. Tumor biopsies 
Tumor biopsies were obtained from colorectal cancer patients after approval of the study 
by the local ethical committee. Patients were not treated with chemotherapy prior to 
resection. Biopsies were snap frozen in liquid nitrogen immediately after resection. Frozen 
blocks were disintegrated mechanically and total RNA was isolated by homogenization in 
TRIzol-Reagent (Gibco BRL), as described below. 
 
5.1.1.2. Cell lines  
Colon carcinoma cell lines HT-29 and SW-480 were purchased from the American Type 
Culture Collection (ATCC). 
HT-29 - DSMZ Nr. ACC 313 
SW-480 - DSMZ Nr. ACC 299 
The establishment and characterization of the low passage number cell lines COGA-1 and 
COGA-3 has been described previously (Vécsey-Semjen et al., 2002). COGA-1 was 
derived from a high-grade mucinous carcinoma of the coecum; this tumor can be classified 
as hereditary non-polyposis colon cancer (Lynch II). COGA-1 cells did not show 
chromosomal instability.  
All cell lines were cultured in RPMI 1640 medium (Life Technologies, Inc) containing 
10% fetal calf serum (FCS; Greiner GmbH), 200 mM L-Glutamine (Life Technologies, 
Inc), 100 mM sodium pyruvate (Gibco BRL) and 100 µg/ml gentamycin (Gibco BRL). 
Cells were cultivated in either coated culture tissue plasticware (Greiner Labortechnik) or 
non-coated Petri dishes for microbiology (Greiner), as indicated in the Results section. All 
cultures were maintained by continuous passaging (on average two times a week) when 
subconfluent: plates were washed once with phosphate-buffered saline (PBS), then 
trypsinized once with 2.5 x trypsin- ethylenediaminetetraacetic acid (EDTA) (0.125% 
trypsin in 1.325 mM EDTA 4Na; Biochrom AG) in PBS (137 mM NaCl, 2.7 mM KCl, 4.3 
mM Na2HPO4*7 H20, 1.4 mM KH2PO4, pH 7.3). Trypsinization was stopped with medium 
containing 10% FCS; cells were centrifuged at 120 x g for five minutes and resuspended in 
fresh medium in appropriate dilutions.  
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All cell lines were grown in a humidified incubator at 37°C and 5% CO2. For storage, cells 
were frozen in liquid nitrogen in RPMI 1640 medium containing 20% FCS and 10% 
DMSO (Sigma Chemicals).  
Cells were checked for mycoplasma contamination by Stratagene Mycoplasma PlusTM 
PCR Kit according to the manufacturer’s protocol. 
 
5.1.2. Antibodies 
Name Company, Product species Epitope recognized Dilution 
phospho (p)-Tyr 
Stat3 
Cell Signaling, 9131 
 
rabbit 
Y705 p-92 Stat3-α & p-83 
Stat3-ß 
1:1,000 
Stat3 C-20 
Santa Cruz, sc-482X, 
91065 
rabbit p-92 Stat3 C-terminus 1:1,000 
goat anti-rabbit 
IgG-POD 
Sigma rabbit  1:10,000
MMP-1 Calbiochem mice  1:50 
 
5.1.3. Other reagents 
Cell biological solutions and reagents were obtained from Greiner, Biochrom, Sigma 
Aldrich, DIFCO; reagents used for biochemical assays (salts, acids, buffers, etc.) were 
commercially available analytical-grade reagents from Sigma Aldrich, Roth, Fluka, R&D 
Systems, Bio-Rad, Gibco BRL and Serva with qualities “pure for analysis” ≥99%. IL-6 
was purchased from R&D Systems GmbH (Wiesbaden). Human MMP-1 
promoter/luciferase reporter plasmid was obtained from Prof. C. E. Brinckerhoff 
(Dartmouth Medical School, Hanover, New Hampshire). Retroviral constructs were 
generated by Dr. E. Pfitzner (Georg-Speyer-Haus, Institute for Biomedical Research, 
Frankfurt am Main). cDNA macroarrays on nylon membranes substrates were generously 
provided by Prof. B Wiederanders (Friedrich-Schiller University Jena Medical School, 
Institute of Biochemistry, Jena). 
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 5.2. Methods 
 
5.2.1. Cell biological methods 
5.2.1.1. DNA constructs   
 The humane MMP-1 promoter/luciferase reporter plasmid -4372 (“hMMP-1luci”) 
(bacterial vector pGL3, ampicillin-resistant), used in this study contains the firefly 
luciferase gene under the transcriptional control of the MMP-1 promoter and was obtained 
from Prof. C. E. Brinckerhoff (Dartmouth Medical School, Hanover, New Hampshire). A 
variant of the MMP-1/luciferase construct contains a single nucleotide polymorphism 
(SNP) located at -1607 bp, where an insertion of a guanine base (G) creates the sequence, 
5’-GGAT-3’, the core binding site for members of the Ets family of transcription factors 
(Wasylyk et al., 1993). The 4.3 kb MMP-1 promoter DNA fragment containing 1 G or 2 
G, respectively, at -1607 bp (Fig. 3) and the MMP-1 promoter/reporter plasmids have been 
described previously (Rutter et al., 1997; Rutter et al., 1998). 
 
 
5´-GTTAAATAAT  TAGAAA   TA   TGACTTATCT  CAAATCAATC-3´
MMP-1-LUC-4372bp
GA
GGA-1622 bp -1583 bp
 
Fig. 3: Segment of the MMP-1 promoter containing the SNP (for details see text). 
 
 
5.2.1.2. Cell Stimulation with Cytokines and Conditioned Media 
For cytokine stimulation, HT-29 or COGA-1 cells were incubated with 20 ng/ml 
recombinant human IL-6 (R&D Systems GmbH, Wiesbaden) medium for 30 min (western 
blot), overnight (reporter gene assay) or 24 h (expression analysis) at 37°C. Cells were 
harvested at 80% confluence after three PBS washes at 4°C. Whole cell extracts were 
prepared from cell pellets as described in 5.2.3.1..  
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 A conditioned medium from cells cultivated on a non-coated plastic surface was obtained 
by seeding 1.8 x 106 cells from a confluent cell culture flask into 8 ml RPMI 1640 and 
incubating this cell suspension in a microbiological Petri dish for 4 days. After this period, 
medium was cleared from cells by centrifugation (10 min at 120 x g), and passed through a 
sterile filter with a pore size of 0.2 µm (Greiner). For stimulation experiments, cells in 
tissue culture flasks were incubated with undiluted conditioned medium for 30 min and 
further treated for cytokine stimulation assays.  
 
5.2.1.3. Long-term Cell Proliferation Assay  
Aliquots of 105 cells were suspended in 2 ml RPMI 1640 medium and allowed to adhere 
in individual wells of 6-well cell culture plates (Greiner bio-one). They were grown in the 
absence or presence of 20 ng/ml IL-6 for up to nine days. Medium with or without 
cytokines was changed every two days. At intervals, cells from individual wells were 
detached from the plastic surface in 0.5 ml 0.05% trypsin/0.02% EDTA (Biochrom, 
Berlin) for 2 min at 37° C before 1.5 ml medium was added to restore the original volume. 
Aliquots of cell suspensions were stained with 4% trypan blue (Sigma) in 0.9% NaCl and 
counted using a Neubauer chamber. The cell concentration was then extrapolated to the 
total volume of the culture.  
 
5.2.1.4. Soft Agar Assay for Anchorage-Independent Growth 
Stat3 induced cell transformation was analyzed using soft agar assay performed as 
described in Huang et al. (2001). Anchorage-independent growth has been shown to 
correlate with tumorigenicity (Huang et al., 2001). Briefly, cells were assayed by seeding 
10,000 cells in 500 µl 0.6% agar (Agarose nobile, DIFCO) diluted in RPMI 1640 medium 
with 10% FCS into six-well plates lined previously with 500 µl 0.5% agar medium (Fig. 
4). The plates (in triplicate and repeated twice) were cultured at 37°C for 2-3 weeks for 
various experiments, and 250 µl fresh medium was added every three days. The colonies 
then were stained with 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyl tetrazolium bromide 
(MTT, 500 µg/ml, Sigma) at 37° C for 2 h before photographing and counting.  
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0.5 % agar
0.6 % agar + 104 cells
RPMI-Medium
 
Fig. 4: Schematic representation of the soft agar assay. 
 
5.2.1.5. In vitro Cell Invasion Assay 
Cell invasiveness was determined by the modified Boyden Chamber method. Each plate 
contains 6 usable transwells (CORNING COSTAR Corporation, Cambridge, MA 02040 
USA), consisting of a separate top well which contains the filter, and a corresponding 
lower well. The upper side of polycarbonate membranes (6.5 mm in diameter, 8 µm pores) 
was coated with 200 µl Matrigel (Becton Dickinson, Bedford, MA) diluted 1:50 with ice-
cold serum-free RPMI 1640 (40 µg/filter), then dried overnight at 37° C.  
In order to determine the invasive properties of each cell line, 2×105 cells were suspended 
in 1 ml RPMI 1640 supplemented with 0.1% FCS and plated on the Matrigel-coated filters 
(Fig. 5). As chemoattractant, 2 ml medium with 10% FCS was used in the lower 
compartment of each transwell unit. IL-6 (20 ng/ml) was added to the cell medium 24 h 
before the assay, and was maintained throughout the entire cultivation period. After 24 h 
of incubation, cells that had invaded the lower compartment of the system were 
centrifuged (120 x g for 5 min at 20°C), resuspended in 1 ml of medium, stained with 
trypan blue and counted under a microscope in four predetermined fields at a 
magnification of 200 x. Results are expressed as percentages of invasive cells compared to 
the total number of cells initially placed in the upper compartment of the chamber. The 
average percentage from three wells was determined, and the entire invasion assay was 
performed at least four times. 
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 Upper 
Compartment
Lower
Compartment
Matrigel
Membrane
 
Fig. 5: Schematic representation of the Matrigel-
based in vitro invasion assay in a modified Boyden 
chamber. Active penetration of the Matrigel layer by 
colon carcinoma cells as a result of the release of 
matrix-degrading enzymes is indicated. Most invasive 
colon carcinoma cells that penetrate the Matrigel and 
cross the micropore filter (8 µm pore size) do not 
adhere to the lower surface of the filter and can be 
recovered from the lower compartment 24 hours after 
placing the total colon carcinoma cell population in 
the chamber. 
 
 
5.2.2. Immunological methods 
5.2.2.1. Immunohistology 
Experiment was performed by Dr. Schütz (University of Leipzig, Institute of Pathology). 
Briefly, tissue was embedded in paraffin and subsequently cut into 4 µm-thick sections. In 
order to reduce endogenous peroxidase activity, the deparaffinized sections were treated 
with 0.3% H2O2. After blocking unspecific binding sites with normal goat serum (Dako 
Diagnostik), the sections were incubated with the monoclonal antibodies (dilution 1:50, 
4°C, overnight), followed by goat-anti-mouse biotin and streptavidin-horseradish 
peroxidase (BioGenex, San Ramon, Calif., USA) and developed with diaminobenzidine. 
Finally, all specimens were coverslipped using Aquatex (Merc, Darmstadt, Germany). 
Negative controls were performed using an irrelevant monoclonal antibody. 
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 5.2.2.2. Cytokine Determination in Cell Supernatant 
The “RayBioTM Human Cytokine Array“ protein array system (Tebu) was used according 
to the manufacturer’s instructions.   
Two array membranes spotted with 79 capture antibodies, six positive controls and three 
negative controls (Tab. 4) were blocked with 2ml 1 x Blocking Buffer (Tebu-bio) at room 
temperature for 30 min. Membranes were then incubated with 1 ml of conditioned medium 
at 4°C overnight. After an extensive washing with Wash Buffer I and II (Tebu-bio) to 
remove unbound cytokines, membranes were then incubated with biotin-conjugated 
anticytokine antibodies, at a dilution 1:1,000 with Blocking Buffer for 1 h at room 
temperature. After washing, membranes were incubated with streptavidin-horseradish 
peroxidase conjugated antibodies at a dilution 1:1,000 with 1 x Blocking Buffer for 1 hr at 
room temperature. Unbound materials were washed off. Finally, the signals were detected 
using the “Chemiluminescence imaging system” (Tebu-bio). The relative expression levels 
in protein arrays were determined by densitometry as described in Section 4.2.4.5. Positive 
control was used to normalize the results from the 2 membranes being compared. 
 
 Tab. 4: The pattern of cytokine capture antibodies on the “RayBioTM Human Cytokine Array” 
PosPosNegTIMP-2TIMP-1TGF-ß3TGF-ß2PIGFPARCOsteoprotegerinNT-4
NT-3NAP-2MIP-3 αMIFMCP-4LIGHTLIFIL-10IL-16IGFBP-4IGFBP-3
IGFBP-2IGFBP-1HGFGDNFGCP-2Fractal-kine
Flt-3 
LigandFGF-9FGF-7FGF-6FGF-4
Eotaxin-3Eotaxin-2EotaxinCkß 8-1BLCBDNFLeptinPDGF-BBVEGF
Thrombopo
ietin
Oncostatin
M
AngiogeninIGF-IEGFTNF-ßTNF- αTGF-ß1TARCSDF-1SCFRANTESMIP-1δ
MIP-1ßMIGMDCMCSFMCP-3MCP-2MCP-1IFN-γIL-15IL-13IL-12 p40/p70
IL-10IL-8IL-7IL-6IL-5IL-4IL-3IL-2IL-1ßIL-1 αI-309
GRO-αGROGM-CSFGCSFENA-78NegNegPosPosPosPos
KJIHGFEDCBA
 
Abbreviations: Pos, positive control; Neg, negative control. All other abbreviations used are 
standard. 
 
 
5.2.2.3. Analysis of MMP-1 Activity 
The levels of active MMP-1 in the supernatants from the HT-29 colon carcinoma cells 
were determined, using the commercially available “Human active MMP-1 Fluorescent 
Assay Fluorokine E” (R&D Systems) (Fig. 6).    
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Fig.  6: Principle of the Fluorokine E human active MMP-1 activity assay (schematic). 
 
An Immunoassay was performed according to the manufacturer’s instructions (R&D 
Systems). The HT-29 cells were cultured for 4 days to confluency in RPMI 1640 with 10% 
FCS in the presence or absence of 20 ng/ml IL-6. After centrifugation (4°C; 120 x g; 5 
min), 150 µl of supernatant from HT-29 cells and varying concentrations of MMP-1 
standard were added to 96-well plates, containing 100 µl of Assay Diluent buffer, in 
duplicate. The plates were incubated for 3 h at room temperature on a horizontal orbital 
microplate shaker set. Unbound materials were washed out four times with 200 µl of Wash 
Buffer (R&D Systems). 200 µl of the activation reagent (0.5 M 4-aminophenylmercuric 
acetate (APMA) in dimethyl sulfoxide (DMSO) were added to each standard well for pro-
MMP-1 activation. The plates were incubated for 2 h at 37°C in a humidified environment. 
After washing, 200 µl of 1 mM fluorogenic substrate in DMSO (R&D) were added for 20 
h at 37°C. The relative fluorescence units (RFU) of each well were determined by using a 
fluorescence plate reader (SOFT max PRO 3.1.1) with the following parameters: excitation 
wavelength set to 320 nm and emission wavelength set to 405 nm. The duplicate readings 
for each standard, control, and sample were averaged. Standard curves (Fig. 7) were 
generated by plotting the mean RFU for each standard on the y-axis against the 
concentration on the x-axis. The concentrations of different samples were determined from 
the standard curves. 
 
Fl FlFl Q
Pro-Leu-Gly-Leu-Ala-Arg-NH2
Fl Q
Pro-Leu-Gly- Leu-Ala-Arg-NH2
Q 
Leu - Ala - Arg - NH2 QLeu-Ala-Arg-NH2
Pro-Leu-Gly Pro-Leu - Gly Fl=Fluorophore
Q=Qencher
Capture sample / standard , 
Activate
Add quenched fluorogenic
substrate
Cleavage of peptide linker 
by active enzyme 
MATERIALS AND METHODS                                                                                                           37
 
Fig. 7: A standard curve for the active MMP-1 in HT-
29 colon carcinoma cells. The addition of APMA to the 
standard (0 - 25 ng/ml of pro-MMP-1) caused activation 
of MMP-1, this was accompanied by a proportional 
increase of the fluorescence level. 
 
 
5.2.3. Western Blot 
5.2.3.1. Preparation of Cell Extracts 
Culture dishes of adherent cells were rinsed twice with ice-cold PBS, cells were scraped 
off and pelleted by centrifugation (5 min, 480 x g). Pellets were mixed with WCE-buffer 
(20 mM Hepes, pH 7.9, 400 mM NaCl, 1 mM EDTA, 20% glycerol, 1 mM dithiothreitol, 
0.2 mM phenylmethylsulfonyl fluoride, 5 µg/ml leupeptin, and 100 µM sodium ortho-
vanadate) and vortexed extensively, followed by 3-4 freeze-thaw cycles in liquid nitrogen. 
The extracts were cleared by centrifugation at 19,000 x g for 30 min at 4° C. Supernatants 
were subjected to protein determinations followed by Western blots or stored at –80°C.  
 
5.2.3.2. Determination of Protein Concentration 
Protein concentration was determined by a Bradford assay (BIO-RAD) compared with a 
standard curve of bovine serum albumine (BSA) (New England BioLabs), dilution series 
0-20 mg/ml, according to the manufacturer’s protocol and measured with Spekol 1200 
(Analytik AG, Jena) in RotiR Quant Cuvette (ROTH), λ=595 nm. 
 
5.2.3.3. SDS-Polyacrylamide Gel Electrophoresis 
Discontinuous SDS-PAGE gel electrophoresis under denaturing conditions was carried out 
according to standard procedures using the Mini Gel system (BIO-RAD). 
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For Western blots a 7.5 % separating gel was used (for higher densities the recipe was 
adjusted). For two gels:  3.3 ml distilled water 
2 ml running gel buffer (1.5 M Tris pH 8.0) 
2.5 ml acrylamide (AA:bis-AA = 39:1; BIO-RAD) 
4 ml Glycerine (40%) 
       50 µl 20% sodiumdodecylsulfat (SDS) 
50 µl 10% APS 
10 µl N`N`N`N-tetramethyl-ethylendiamin (TEMED) (Electran; 
BDH) 
Stacking gel: 2 ml distilled water 
1.3 ml stacking gel buffer (0.5 M Tris pH 6.8) 
0.7 ml acrylamide 
1 ml Glycerine 
25 µl 20% SDS 
40 µl APS 
10 µl TEMED 
 
20 µg of whole cell extract were solubilized in gel loading buffer (62.5 mM Tris/ HCl pH 
6.8; 2% SDS; 25% Glycerol; 1‰ phenolblue; 5% ß-mercaptoethanol), boiled for 10 min 
and separated on a 10% acrylamide SDS Gel. The gel run was performed (in 25 mM Tris 
Base, 250 mM glycine pH 8.3, 0.1% SDS) at 120 V until the front reached the bottom.  
 
5.2.3.4. Semi-dry Electroblotting  
Proteins were transferred from the gel onto a nitrocellulose membrane (Schleicher&Schüll 
GmbH) by electro-blotting in semi-dry blotting buffer (1 L: 3.23 g glycine, 5.8 g Tris pH 
7.5, 1.7 ml 20 % SDS, 200 ml methanol) at 0.8 mAmp/cm2 membrane for 60 min. 
 
5.2.3.5. Immunoblotting 
The membrane was stained with Ponceau-Red (0.1% Ponceau-Red in 5% acetic acid; 
Sigma) to check for successful transfer and equal loading, then nitrocellulose membranes 
were blocked in 1 x NET-G buffer (10 x :1.5 M NaCl, 50 mM EDTA, 500 mM Tris-HCl 
pH 7.5, 0.5% Triton X-100, 0.2% Gelatine, Serva-researchgrade № 22151) for 1 hour at 
room temperature. The first antibody Stat3 p-Tyr 705 (Cell Signaling Technology, Beverly 
MA) and Stat3-α (c-20, Santa Cruz) were diluted in blocking solution and incubated for 36 
h in a 1:1,000 dilution at 4°C. Then the membrane was washed 5 times for 10 min each in 
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NET-G, incubated for 1 h at room temperature with a secondary antibody, peroxidase-
conjugated anti rabbit IgG (Roth), at a dilution of 1:10,000, then washed again 5 times for 
10 min each in NET-G. Detection was achieved by ECL (enhanced chemiluminiscence 
detection; Amersham Pharmacia Biotech) for 1 min. This method is based on an enzymatic 
reaction, performed by the secondary antibody-coupled horseradish peroxidase, which 
leads to emission of light that can be detected on an X-ray film - HyperfilmTMECLTM 
(Amersham Pharmacia Biotech). Protein size was determined by comparing the migration 
distance in the gel with the position of the bands of a prestained molecular weight marker 
SDS-7B (SIGMA).  
 
5.2.3.6. Stripping of Blots 
Blots were stripped for 30 min at 55°C, while being shaken in 2% SDS, 50 mM Tris-HCl 
pH 6.7, 100 mM β-mercaptoethanol. The membrane was then carefully washed in large 
volumes of NET-G, blocked again, and the standard procedure was repeated with another 
antibody. 
 
5.2.3.7. Coomassie Staining 
Coomassie staining was used to compare the quality and concentration of the samples. 
Gels were stained for about 30 min in 40% methanol, 10% glacial acetic acid, 0.25% 
Coomassie R250 (Serva) and subsequently destained in 40% methanol, 10% glacial acetic 
acid until bands were clearly visible. Gels were then dried on filter paper.  
 
5.2.4. RNA and DNA Analytical Methods   
5.2.4.1. RNA Extraction 
Frozen blocks of colon carcinoma tumor samples were disintegrated mechanically. HT-29 
cells were placed in 100-mm plates at 1.8 x 106 cells/plate and grown to 80% confluency 
(48-72 h). After that, cells were washed with 5 ml ice–cold PBS. The total cellular RNA 
was isolated from confluent monolayers of cells or cryopreserved human colonic tumor 
resection specimens using TRIzol-Reagent (Gibco BRL) and the protocol provided by the 
manufacturer. One ml TRIzol was resuspended with 100 mg tumor sample or HT-29 cells, 
then 200 µl chloroform was added and samples were shaken gently by hand for 15-30 sec 
then incubated at room temperature for 2-3 min. Then they were centrifuged at 16,000 x g 
for 15 min at 4° C. The upper aqueous phase of each of the samples containing RNA was 
transferred to new 2 ml sterile tubes, and 200 µl Isopropyl alcohol was added. The 
samples were vortexed vigorously and incubated at RT for 10 min. Then they were 
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centrifuged at 16,000 x g for 10 min at 4° C and the supernatants were carefully removed 
so as not to disturb the RNA pellets. The pellets were washed using 75% Ethanol (1 ml) 
and centrifuged at 6,000 x g for 5 min at 4°C. Then the pellets were dried for 10-20 min at 
room temperature. After addition of 20-30 µl RNase-free H20, the RNA was quantified by 
optical density in “HELLMAR-Quarzglas-SUPRASILR-Cuvette (Type No.105.202.008-
QS, “QS1000” light path 10 mm) using a spectrophotometer “Gene QuantII RNA/DNA 
Calculator” (Pharmacia Biotech) set at an absorbance level of 260 nm. The quality of 
RNA was checked by the electrophoresis of 1 µg samples in 1.5% agarose gel (Gibco 
BRL) in TRIS/ACETATE/EDTA buffer (TAE), previously stained with 2.5 µl ethidium 
bromide (10 mg/ml, BIO-RAD), and visualized under UV light. The size of RNA 
fragments was determined by a comparison with DNA ladders (1 kb or 100 bp ready load; 
Gibco BRL). No significant degradation was observed in any RNA sample. All the RNA 
samples were stored at -80°C prior to reverse transcription.  
 
5.2.4.2. Reverse Transcription 
First strand cDNA was synthesized from 5 µg total RNA using M-MLV RNase H(-) Point 
Mutant reverse transcriptase (Promega Corp., Madison, WI) in a final volume of 30 µl. 
Total RNA was first incubated with 750 ng Oligo-dT15-Primer (Promega Corp., Madison, 
WI) or 200 ng of random hexameres (Promega Corp., Madison, WI) in a preheated PCR 
thermal cycler “TECHNE” (PROGENE) at 65°C for 15 min, then cooled on ice for 5 min. 
The following contents were combined in a labelled 0.25 mL PCR tube and mixing by 
pipetting: 1 x reverse transcriptase (RT) buffer (Promega Corp., Madison, WI), 1 mM 
dNTP mixture (Amersham Pharmacia), 10 mM dithiothreitol (DTT) (Invitrogen), 20 units 
of RNAsin recombinant ribonuclease inhibitor (Promega Corp., Madison, WI), 240 units 
of M-MLV reverse transcriptase and diethylpyrocarbonate treated water. To generate 
digoxigenin-labeled cDNA macroarray probes, 2 µl of one mM Digoxigenin-dUTP 
(Roche) was added to the reaction mix. The tubes were replaced in the PCR thermal 
cycler. After incubation at 42°C for 75 min, the RT reaction was terminated by heating at 
72°C for 15 min. The reaction was stopped by addition of 1 µl EDTA (200 mM). Then 3 
µl of 4 M LiCl and 90 µl of ice-cold 100% ethanol were added and samples were 
incubated at -80°C for 30 min. After centrifugation at 19,000 x g for 15 min at 4°C the 
supernatants were then carefully removed so as not to disturb the cDNA pellets, and the 
pellets were washed using 70% ethanol (500 µl). The samples were centrifuged at 6,000 x 
g for 5 min at 4°C; pellets were dried for 10-20 min at room temperature and 50 µl of TE-
buffer was added. Five µl of the RT samples were electrophoretically separated on 1% 
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agarose gel (Gibco BRL) in TAE previously stained with ethidium bromide (BIO-RAD), 
and visualized under UV light. Size of cDNA was determined by comparison with DNA 
ladders (1 kb or 100 bp ready load; Gibco BRL). The newly synthesized cDNA was 
amplified by TaqMan Real-Time PCR or hybridized in human cDNA macroarray system 
(Fig. 8). 
 
28S
18S
5S
total RNA
cDNA-ArraycDNA
1kb 
DNA ladder 
 
Fig. 8: Quality control of total RNA and cDNA employed in cDNA macroarray experiments 
(for details see text). 
 
5.2.4.3. Protease Expression Analysis by cDNA Arrays 
cDNA macroarrays on nylon membranes substrates were prepared as follows: PCR 
fragments of 200- to 500 bp length were derived from cDNAs representing the following 
collection of human intra- and extracellular proteases and protease inhibitors: matrix-
metalloproteinases; membrane-type matrix metalloproteinases; a disintegrin and 
metalloproteases ADAM; cathepsins; tissue inhibitors of metalloproteinases; caspases; 
urokinase-type plasminogen activator uPA, urokinase-type plasminogen activator receptor 
(uPAR); integrins; plasminogen activator inhibitors PAI; cystatins; tumor necrosis factor α 
converting enzyme (TACE), emmprin, heparanase, tissue factor, granzyme H and bikunin 
(Tab. 5). 
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Tab. 5: A map for the location of cDNA spotted onto human cDNA macroarray 
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 To represent "housekeeping genes", probes for the following cDNAs were also included: 
ß-actin, transcription factor c-ets-1, carcinoembryogenic antigen (CEA), glyceraldehyde-3-
phosphate dehydrogenase (GAPDH),  ubiquitin, elongation factor EF1 α and ribosomal 
protein S9. PCR fragments were purified by preparative agarose gel electrophoresis and 
concentrations were adjusted to 20 ng/µl in H2O. DNA solutions were heated to 95oC for 5 
min, chilled, then exposed to 100 mM NaOH for 20 min at room temperature. 
Subsequently, samples were adjusted to 2 x sodium chloride and sodium citrate solution 
(SSC)/125 mM Tris/HCl pH 7.5. Aliquots containing 5 ng were spotted in duplicate onto 
positively charged nylon membranes (1 417 240, Roche) 7 x 10 cm in size.  
PCR primers used to generate the probes are shown in Tab. 6. Membranes were 
stored at -20oC and used for comparative analysis of cDNA obtained from tumor samples 
or HT-29 cells transfected with Stat3 derivatives.  
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 Tab. 6: Primers for human cDNA macroarrays 
Primername Dimension Primersequenz sense Primersequenz antisense 
hADAM 81/ 2 523 bp 5´-cct gca tga caa cgt aca gc -3´ 5´- gca ctc ctg gca gca ggt ac-3´ 
hADAM 91/ 2 694 bp 5´-act tta gca gtt gca gtg ca -3´ 5´- gga aga tct gat cct agc tg-3´ 
hADAM 101/ 2 590 bp 5´-gat gaa tgc tgc ttc gat gc-3´ 5´- tga gcc aca atc cat tca gc-3´ 
hADAM 111/ 2 524 bp 5´-cca ctg ttc gag cag atg c-3´ 5´- ctg gtt gta ctc gtc gat gc-3´ 
hADAM 151/ 2 471 bp 5´-agg tgc aca gtg tgc atc tg-3´ 5´- cag ctg cag ttc agc tca gt-3´ 
hTACE1/ 2 724 bp 5´- tgt gaa gat gtt gct aga gc –3´ 5´- ctc act gct att acc tgt gc -3´ 
hADAM 201/ 3 702 bp 5´- gca cac cag atg gag ttg ca-3´ 5´- cca cta gat tcc cac agt ac-3´ 
hADAM 211/ 2 585 bp 5´-ctt ggc cta gcc tat gtt gc-3´ 5´- agt agg cac tgt cac tac ag-3´ 
Integrine    
halpha21/ 2 722 bp 5´-gac aag tgg ttc aac tct ggt ca-3´ 5´-agc agg gta gcc tac atc gc-3´ 
halpha41/ 2 674 bp 5´-gct gat tta cag gtt tct gca-3´ 5´-tgg cat tct cca gta gta gtc-3´ 
halpha51/ 2 493 bp 5´- cca cca tgt cta tga gct ca -3´ 5´- ctt ggt cca ttg cac agc tg -3´ 
halpha61/ 2 500 bp 5´-gta cag ttg ttg gcg agc aag-3´ 5´-gaa ggc tcg cat gag aat gtc-3´ 
halphaV1/ 2 735 bp 5´-ctt agc aag act ttc ctg tgc-3´ 5´-gtc tca gtc cac agt aat gac-3´ 
hbeta11/ 2 514 bp 5´- gtt ggt aga cat tgt gaa tgc -3´ 5´- agg aac att cct gtg tgc atg –3´ 
hbeta21/ 2 562 bp 5´-tgc acg aag ttc aag gtc ag-3´ 5´-tgg tca gct tca gca cgt gc-3´ 
hbeta31/ 2 667 bp 5´- atg gac ctg tct tac tcc atg  -3´ 5´- cat tgc tgg aat cca tgg ac -3´ 
hbeta41/ 2 620 bp 5´-acc tgt aca tcc tca tgg ac-3´ 5´-gtg aag ctt ctc gta gta gc-3´ 
hbeta51/ 2 632 bp 5´- agt tgt cag tct ggg atc ag –3´ 5´- tgt gct gat gtc tgt cga gc –3´ 
hbeta71/ 2 675 bp 5´-cta cct tat gga cct gag ct-3´ 5´-tgt acc acg ttg ctg gag tc-3´ 
    
hBikunin1/ 2 606 bp 5´-tac aat gtc act gac gga tc-3´ 5´- cat atg tgt tct tca cca gct-3´ 
hbAktin1/ 2 635 bp 5´- acc acg gcc gag cgg gaa atc  -3´ 5´- gag ccg ccg atc cac acg gag ta -3´ 
    
hCaspase 1 1/ 2 701 bp 5´-aga ccc gag ctt tga ttg act-3´ 5´- acg gca ggc ctg gat gat ga-3´ 
hCaspase 2 3/ 4 897 bp 5´- gga cgc agg ata ttg gga gtg tg- 3´  5´- acg gca ggc ctg gat gaa gaa-3´ 
hCaspase 3 1/2 
(CPP 2/ CPP 3) 1037 bp 5´- agt tag cga gcc ctg ctc aca ctc-3´ 5´- tac cct ctg cag cag gagagt agg tc-3´ 
hCaspase 4 1/ 2 1137 bp 5´- tgt tcc cta tgg cag aag g-3´ 5´- tgc cag gaa aga ggt aga aat-3´ 
hCaspase 6 1/ 4 624 bp 5´-cgc gtt tgg ctg caa tga gc-3´  5´- ctc cag cag gca gcg tgt aa(a) c-3´ 
hCaspase 7 1/ 2 912 bp 5´- atg gca gat gat cag ggc tgt att-3´ 5´- cta ttg act gaa gta gag ttc ctt ggt ga-3´
hCaspase 8 4/ 5 670 bp 5´- caa acc tcg ggg ata ctg tct gat-3´ 5´- ctg ttt ccc cat gtt ttt ctt gtc-3´ 
hCaspase 9 3/ 4 1016 bp 5´- agg aca tgc tgg ctt cgt ttc t-3´ 5´- gcc ctg gcc tta tga tgt ttt a-3´ 
hCaspase 10 3/ 4 813 bp 5´- aag ccg agt cgt atc aag gag agg-3´ 5´- cca ggg gca cag gga ata cta-3´ 
    
hCathepsin B 1/ 2 539 bp 5´- gca gcc tca gcc acc cag at-3´ 5´- cca cca tta cag ccg tcc cca cac-3´ 
hCathepsin D 1/ 2 895 bp 5´- cac ggg ctc ctc caa cct gt-3´ 5´- agt gta gta gcg gcc gat gaa gac-3´ 
hCathepsin F 1/ 2 582 bp 5´- cgg gcc aag ggt cgc tgt a-3´ 5´- act tgg ctt gct tca tct tgt tgc-3´ 
hCathepsin H 1/ 2 646 bp 5´- cgt gga ctg gcg gaa aaa-3´ 5´- cag agg gat ggg gta gga g-3´ 
hCathepsin K 3/ 4 514 bp 5´- gtg tgg ttc ctg ttg ggc ttt tag-3´ 5´- tcc ttt gtt tcc cca gtt ttc tcc-3´ 
hCathepsin L 1/ 2 612 bp 5´- ccg ggg agg gca gtt gag-3´ 5´- cct tga ggc cca gag cag tc-3´ 
hCathepsin S 1/ 2 664 bp 5´- atg gca aac aat aca agg aa-3´ 5´- tga cgc gca tct aca cc-3´ 
hCathepsin V 1/ 2 742 bp 5´- ata tgg cgc gaa tga aga agg atg-3´ 5´- aaa gcc gta gcc aac cac  cag aac- 3´ 
hCathepsin W 1/ 2 750 bp 5´- tgc tca ccg cct gga cat ctt t-3´ 5´- gcc cat atc ccc tcc tct gat ttg-3´ 
hCathepsin Z 1/ 2 521 bp 5´- ggc cct cca ccc tcc tgt c-3´ 5´- ggc gcc ctt ccc atc ctt at-3´ 
    
hCEA 1/ 2 378 bp 5´-tga ata caa gtt tct gat acc ac-3´ 5´- gaa ctt gtg caa taa cta tat tac-3´ 
hc-ets-1 1/ 2 636 bp 5´-gac atc tta tgg gaa cat cta g-3´ 5´- tgg tcc act gcc tgt gta gc-3´ 
hCystA 1/ 2 388 bp 5´-atc ctg tcc agc aaa gaa gc-3´ 5´- cag caa gga tca tga ctc ag-3´ 
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 Primername Dimension Primersequenz sense Primersequenz antisense 
hCystB 1/ 2 370 bp 5´- ggt gag gtc cca gct tga ag  -3´    5´- gca aaa gca gtc gca gaa tc -3´  
hCystC 1/ 2 377 bp 5´-agc aac gac atg tac cac ag-3´ 5´-tct cct ggt gca ggc aca tg-3´ 
hEFa  1/ 2 289 bp 5´-tgc ccc agg aca cag aga ct-3´ 5´-ctg tgt cgg ggt tgt agc ca-3´ 
hEmmpI1/ 2 570 bp 5´-cat gct ggt ctg caa gtc a-3´ 5´-gtg tat gat ggg aat cta cg-3´ 
hEmmpII1/ 2 578 bp 5´- agt gct tgc aag att cca ag-3´ 5´-gct tct gcg gtt ctg gag tc-3´ 
    
hGAPDH 3/ 4 269 bp 5´- ggc tct cca gaa cat cat cc-3´ 5´- ggg tgt ggc tgt tga agt ca-3´ 
hGrzH1/ 2 473 bp 5´-tgc tga cag ctg ctc act g-3´ 5´-gag aat acc ttg ggc tac gt-3´ 
hHepa1/ 2 450 bp 5´-cta cca gga gca att gct ac-3´ 5´-cca ttc aaa tag tag tga tgc-3´ 
hIAP3 1/ 2 512 bp 5´- tgg cac gag cag ggt ttc-3´ 5´- cca ggc acg atc aca agg tt-3´ 
    
hMMP - 1 1/ 2 677 bp 5´- agg gtc aag cag aca tca tg-3´ 5´- agc atc gat atg ctt cac agt -3´ 
hMMP - 2 1/ 2 650 bp 5´- act cag cca gca cct tgg ag-3´ 5´- agc cca aag cag ggc tgc gt-3´ 
hMMP - 3 1/ 2 630 bp 5´-ttg cag tta g(a)g aac atg ga-3´ 5´-atc cag ctc gta cct ca-3´ 
hMMP - 7 1/ 2 519 bp 5´-ggc atg agt gag cta cag tg- 3´ 5´-cca gcg ttc atc ctc atc ga-3´ 
hMMP - 9 1/ 2 610 bp 5´-ctt cta cgg cca cta ctg tg-3´ 5´-cac tgc agg atg tca tag gt-3´ 
hMMP - 11 1/ 2 589 bp 5´-ctc agt act ggg tgt acg acg g-3´ 5´-aca gtc gct ggc agg tga c-3´ 
hMMP - 13 1/ 2 821 bp 5´-gtc tgg aga tat gat gat ac-3´ 5´-cat cta cta ttc tta cca ctg-3´ 
hMT1-MMP 1/ 2 450 bp 5´-gca gaa gtt tta cgg ctt gca-3´ 5´-gca gag tca aag tgg gtg tc-3´ 
hMT2-MMP 1/ 2 469 bp 5´-agt cac cgg tgt gct cga c-3´ 5´-atg cag gtc agt gct gga ga-3´ 
hMT3-MMP 1/ 2 399 bp 5´-agc tcg tcc atc cat tga ag-3´ 5´-tca atg cat atc gct ttc gac-3´ 
hMT4-MMP 1/ 2 568 bp 5´-agc tgt cta agg cca tca c-3´ 5´-cgc atg atg gag tgt gca g-3´ 
hMT5-MMP 1/ 2 658 bp 5´-tga aga ggt gcc ata cca tg-3´ 5´-cca gaa ctg ctc gat ctg ca-3´ 
hMMP - 19 1/2 729 bp 5´-gac cgg gcc cct tgt tcc-3´ 5´-tct acg gtc ttg cgc ctg cta c-3´ 
    
hPAI-1 1/ 2 687 bp 5´- gat cga ggt gaa cga gag t-3´ 5´- cac agt gga ctc tga gat g-3´ 
hPAI-2 1/2 712 bp 5´- atc ctg atg cga ttt tgc ag-3´ 5´- atg ctt ctc aga atg gat ct-3´ 
hPro1073 (1323) 681 bp 5´- taa gct tat tat cta tgg ctg aag  
aca aac ac-3´ 
5´- ttc agt tgc cag gaa aga ggt  
aga aat a-3´ 
    
hR13a 1/2 631 bp 5´- agc ggc tgc c(g)a aga tgg-3´ 5´- tgg gct cag acc agg agt c-3´ 
hrS9 1/ 2 663 bp 5´- cgc agg cgc aga cgg tgg aag c-3´ 5´- tgg cag gaa aac gag aca atc-3´ 
    
hTIMP11/ 2 501 bp 5´-aga cca cct tat acc agc g-3´ 5´-gac act gtg cag gct tca gt-3´ 
hTIMP21/ 2 532 bp 5´-gat cca gta tga gat caa gc-3´ 5´-tgt cag agc tgg acc agt c-3´ 
hTIMP31/ 2 445 bp 5´- ctt ctg caa ctc cga cat cg  -3´ 5´- gta gtg ttt gga ctg gta gc-3´ 
hTIMP41/ 2 534 bp 5´-agt ctt cat cca tct gtg ca-3´ 5´-cag taa cag cta caa ggc tag-3´ 
    
hTF1/ 2 399 bp 5´- ctt cag gca cta caa ata ctg -3´ 5´-aag tcc gtt cat ctt cta cg -3´ 
    
huPA 1/ 2 645 bp 5´-cat caa gtt cca tcg aac tg-3´ 5´-cca ggt aga cga tgt agt c-3´ 
huPAR 1/ 2 907 bp 5´-cat gca gtg taa gac caa cg-3´ 5´-aca gtc tgg cag tca tta gc-3´ 
hUbiquitin 1/ 2 234 bp 5´- atg cag atc ttc gtg aaa acc-3´ 5´- tta aca gcc acc cct cag-3´ 
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Hybridization of labelled cDNAs to protease cDNA macroarrays on nylon membranes was 
done using Dig Easy Hyb (Roche). The membrane was prehybridized overnight at 42°C in 
6 ml of DIG Easy Hyb hybridization solution, supplemented with 150 µg/ml denatured 
herring sperm carrier DNA (Invitrogen). The filter was then hybridized with 50 µl oligo-
dT15-primed Digoxigenin–labeled cDNA probe. After 36 h hybridization at 42°C in 3 ml 
DIG easy hyb hybridization solution and 150 µg/ml denatured herring sperm DNA, the 
membrane was washed once in 2 x SSC with 0.1% SDS, once in 1 x SSC with 0.1% SDS 
at room temperature and then washed three times at 68°C using prewarmed 0.5 x SSC and 
0.1% SDS and twice at 68° C using prewarmed 0.1 x SSC and 0.1% SDS. After that nylon 
membrane (Roche) was blocked in 1 x blocking buffer (Roche) for 1 h and incubated with 
digoxigenin antibody (Roche) for 30 min at room temperature in a 1:10,000 dilution. The 
filters were then washed three times for 10 min in 150 mM NaCl, 100 mM maleic acid (pH 
7.5) and 0.3% Tween-20. Finally, the signals were detected using the Chemiluminescence 
substrate CSPD (Roche). CSPD was diluted 1:100 in detection solution (0.1 M Tris-HCl, 
pH 9.5; 0.1 M NaCl) and membranes were incubated in this solution for 5 min at room 
temperature. The cDNA array membranes were exposed to HyperfilmTMECLTM 
(Amersham Pharmacia Biotech) for 40 min at room temperature and scanned using 
HPScanjet 4470pro scanner (Hewlett Packard).  
 
5.2.4.4. Densitometric Analysis  
For the quantitative analysis of cDNA arrays, the “AIDA” software (version 3.11; Raytest, 
Straubenhardt) was used. First, the contrast of the scanned X-ray film images was 
optimized. Then a grid template (schematic representation of an array) was created to 
associate the correct gene information with the corresponding gene spots. Using orientation 
spots (spots printed along the borders of arrays to help users to orient arrays properly) the 
arrays were matched to the corresponding spots on the grid template. Then the alignment 
was fine-tuned and the grid template lined up closely with the spots. The background value 
was determined by setting the median intensity to match the “blank space” between the 
different panels of the array. The background value is used to calculate the adjusted 
intensity for a gene. After generating a report the following characteristics were shown: 
 
Area  calculated as a dimension of the signals or background in mm2 
Integral calculated as a total signal from the gene spots in pixels (double-spotted 
array) 
The correlation factor and correlation integral were calculated as follows: 
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 cF= A(Signal)/mqA (Background) 
 
cF - correlation factor 
A - Area 
mq - average from the 3 “blank spaces” 
 
cI= I(Signal)-(cF x mqI (Background)) 
 
cI - correlation Integral (adjusted intensity for a gene) 
I – Integral 
 
The signal intensity between the two arrays being compared was normalised. 
Normalisation allows for adjustments to the hybridisation signals if different amounts of 
messenger RNA (mRNA) were used for generating cDNA probes or to correct for different 
exposures. Several studies have demonstrated that the most thorough way to normalise 
mRNA expression levels is to use a set of “housekeeping genes” as hybridisation standards 
(Adams et al., 1995). “Housekeeping genes” produce the mRNAs necessary for a cell’s 
basal metabolism. In contrast to the cDNA included on macroarrays, which are under tight 
transcriptional control, the levels of housekeeping gene transcripts remain relatively 
constant in different tissues, cells, developmental stages, and diseases (Adams et al., 1995). 
The mean signals derived from four “housekeeping“ mRNAs (GAPDH, ß-actin, ubiquitin, 
R13α), spotted on the same membrane, were set as 100% for normalisation. Relative signal 
intensity was expressed as percentage of this maximal intensity. 
 
5.2.4.5. Real-Time Quantitative RT-PCR (qRT-PCR) 
Quantitation of cDNA from specific mRNA transcripts was accomplished by qRT-PCR 
(ABI/Prism® 7000 Sequence Detection System; Applied Biosystems) using TaqMan 
technology (TaqMan Master Mix; Applied Biosystems).  
TaqMan utilizes a gene-specific probe containing both fluorescent and quencher tags, 
which hybridise to the cDNA between the two PCR primers. As PCR proceeds, the 5’ 
nuclease activity of the Taq polymerase cleaves the probe, releasing the tag such that the 
fluorescence is proportional to the amount of specific amplified product present.  
This procedure is based on the time point during cycling when amplification of the PCR 
product is first detected, rather than by the amount of PCR product accumulated after a 
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fixed number of cycles. The parameter threshold cycle (Ct) is defined as the fractional 
cycle number at which the fluorescence generated by cleavage of the probe passes a fixed 
threshold above the baseline. The MMP-1 gene copy number in unknown samples is 
quantified by measuring Ct and by using a standard curve to determine the starting copy 
number, as described by the manufacturer (1997 User Bulletin no.2; Applied Biosystems). 
A standard curve was constructed for both MMP-1 and 18S rRNA gene, as an endogenous 
control (Fig. 9). Serial dilutions (in duplicate) of cDNA (equivalent to a cDNA amount 
from 100 ng to 100 pg of initial total RNA) from HT-29 cells were made in sterile water. 
The series of diluted human cDNAs were aliquoted and stored at -80° C until use. 
The target amounts of the unknown samples were divided by the endogenous reference 
amount to obtain a normalized target value. Final results, expressed as n-fold differences 
in MMP-1 gene expression relative to 18S rRNA gene and calibrator were calculated. 
Direct comparisons between levels cannot be made between different primer/probe sets.  
Pre-designed fluorogenic Assays-on-DemandTM TaqManTM probes and primer pairs for 
MMP-1 (Hs00233958_m1) and 18S rRNA (Hs99999901_s1) were obtained from Applied 
Biosystems Incorporated (Foster City, CA; http://www.appliedbiosystems.com). The 
MMP-1 and 18S rRNA 18uM gene specific primers predicted to amplify 150- and 120 bp 
DNA fragments, respectively.  
The following FAM (6-carboxy-fluorescein)-labeled probes were used for PCR 
amplification: 
MMP-1 gene  5’ AAAGACAGATTCTACATGCGCACAA 3’ 
18S rRNA gene 5’ TGGAGGGCAAGTCTGGTGCCAGCAG 3’ 
qRT-PCR was performed using a 96-well optic tray on the ABI Prism 7000 sequence 
detection system (Applied Biosystems). A total reaction volume of 25 µl contained the 
12.5 µl of 2 x TaqMan Universal Master Mix, No AmpErase UNG (Applied Biosystems, 
part number 4324018), 3 µl cDNA (described above), 1.25 µl of 20 x Assays-on-
DemandTMGene Expression products (Applied Biosystems, part number 4331182) for 
MMP-1, consisting of  
20 x mix of unlabeled PCR primers and 5 uM TaqMan MGB probe (FAM dye-labeled 
MMP-1), and sterile water. The PCR thermal cycle condition was set up at 95°C for 10 
min followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. 
For each reaction well, the fluorescence signal of the reporter dye (FAM) is divided by the 
fluorescence signal of the passive reaction dye (ROX) to obtain a ratio defined as the 
normalized reporter signal. Experiments were performed in triplicate for each sample data 
MATERIALS AND METHODS                                                                                                           49
bpoint. Each PCR run included the four points of the standard curve, a no-template control, 
and the unknown cDNAs. Data collection and analysis was performed with SDS version 
1.0.1. Software (Applied Biosystems). Data were then exported and further analyzed in 
Excel (Microsoft, Redmond, WA). 
 
            
Fig. 9: Representative quantitative real-time RT-PCR analysis for MMP-1 mRNA and 18S 
rRNA copy levels. A: Amplification plot of serially diluted cDNA (100 ng to 100 pg) from HT-29 
cells, tested for 18S rRNA expression as endogenous control (in duplicate). Delta Rn on the Y axis 
indicates the fluorescent signal of the cleaved probe in the amplification reaction, measured real-
time during cycling. The PCR cycles are indicated on the X axis. After a phase with exponential 
amplification (steep part of the curve), the amount of PCR product stabilizes by increasing 
shortage of reagents. The cycle at which the amplification plot crosses the ∆Rn value of ~0,1 was 
defined as CT. B: standard curves for 18S rRNA (below) and MMP-1 m RNA (above) in serial 
dilution ranging from 100,000 to 100 pg of HT-29 cDNA. Both standard curves were made for 
each biopsy sample or cell line. The CT  value was indicated on the Y axis and the amount of 
cDNA (in pg) on the X axis (logarithmic expression). Using the calibration curves of the standard 
cell line HT-29, the amount of MMP-1 mRNA or 18S rRNA in a sample can be quantified 
accurately. 
 
5.2.4.6. DNA Transient Transfection and Luciferase Assay 
HT-29 colon carcinoma cells as well as stable HT-29/Stat3 transfected cells were grown in 
RPMI 1640 medium containing 10% fetal calf serum (FCS). Transfections were 
performed using the PolyFect reagent (QIAGEN) following the manufacturer’s 
instructions. Briefly, exponentially growing HT-29 were plated at a density of 7 x 105 
cells/well in six-well cluster plates (Greiner) in 2 ml RPMI 1640, 10% FCS and grown 
until 80-90% confluent (24-36 h). The cells were then washed, placed in 1 ml/well fresh 
full RPMI 1640, and cotransfected (using Polyfect reagent) with 1 µg of chimeric humane 
MMP-1 promoter/luciferase construct and 0.1 µg of the pRL-TK Renilla luciferase vector 
(Promega) as an internal control for transfection efficiency. Both types of DNA were 
diluted with growth medium containing no serum, antibiotics or proteins, to a final volume 
of 100 µl; the solution was mixed and 9 µl of PolyFect Transfection Reagent/well added. 
A B
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The mixture was incubated at room temperature for 5-10 min to allow complex formation. 
1ml of full medium was added to the complexes and the transfection mixture immediatly 
transferred to the dish. PolyFect is non-toxic, and cells can be incubated until harvest 
without medium change. After 14 h, the cells were gently washed with RPMI 1640 and 
incubated with fresh RPMI containing IL-6 (20 ng/ml). The cells were harvested 8 h later 
using reporter lysis buffer (Promega, Medison, WI). The luciferase and renilla activities 
were determined using the Dual-Luciferase Reporter Assay System kits from Promega 
according to manufacturer’s instructions. Luciferase activity was measured on a Micro 
Luminat LB 96 P Luminometer and reported as relative light units. Three independent 
transfections, each run in triplicate, were performed, and the results were normalized to 
the renilla activity.  
 
5.2.5. Xenograft Experiments 
Experiments were performed by Florian Corvinus and Richard Moriggl. Briefly, a total of 
105 cells of the HT-29 cell line was suspended in PBS and injected subcutanously in a 
volume of 100 µl into the neck of 5-8 week male athymic Hsd:NMRI-nu/nu mice (Harlan). 
Mice were dissected after the tumors had reached a size of approximately 2,000 mm². 
Tumor specimens were treated further in the same manner as the human biopsies (see 
above).  
 
5.2.6. Statistical Analysis  
All numerical values reported represent mean values +/- standard deviation (±S.E.) 
determined by use of Microsoft Excel Software.   
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 6. RESULTS 
 
6.1.  Stat3 activity is associated with enhanced proliferation, 
oncogenic transformation and invasiveness in colon 
carcinoma cell lines 
 
6.1.1. IL-6 activates Stat3 in colorectal tumor cell lines   
Constitutive Stat3 activity was observed in more than 90% of surgical tumor specimens 
from colorectal carcinoma patients by Western blot and Electrophoretic Mobility Shift 
Assay (Corvinus et al., 2004). As high Stat3 activation was also evident in malignantly 
transformed colon epithelium cells, established cell lines (HT-29 and SW-480) and low 
passage cell lines (COGA-1, COGA-3) were employed as model systems to study aspects 
of both origin and consequences of Stat3 activity in colon cancer. These selected cell lines 
have been shown to be very similar and even identical to original tumors concerning many 
properties, e.g., phenotype, markers, genetic changes (Vécsey-Semjén et al., 2002). Each 
human colon carcinoma cell line was analyzed for Stat3 expression and activity, and 
compared to clinical tumor specimens by Western blot using Stat3 or phospho-Stat3 (Tyr 
705) antibodies. All investigated cell lines showed Stat3 expression. However, in contrast 
to surgical tumor specimens, neither HT-29 nor SW-480 cells displayed any constitutive 
activity of Stat3. To answer the question whether cytokines are involved in the activation 
of Stat3, cells were stimulated with various cytokines known to trigger Stat3 via the gp130 
cytokine receptor chain shared by their receptors. Oncostatin M (OSM), Leukemia 
Inhibitory Factor (LIF), and Interleukin-11 did not evoke any detectable Stat3 activity 
(data not shown). In contrast, IL-6 induced profound Stat3 activity in both established 
colon carcinoma cell lines tested as indicated by Western blot with the phospho-Stat3-
specific antibody. Both investigated COGA low passage cell lines also did not exhibit 
constitutive but only IL-6-inducible Stat3 activity (Fig. 10). These results demonstrate that 
constitutive Stat3 activity inherent to tumors is lost during cultivation of cancerous colon 
epithelial cell lines and is regained by cytokine stimulation. 
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Fig. 10: Analysis of Stat3 activity in colon carcinoma cell lines following IL-6 treatment. 
HT-29, COGA-1, COGA-3 and SW-480 cells were incubated (+) with 20 ng/ml of IL-6 for 30 
min or left untreated (-). 20 µg of protein obtained from whole cell extracts were suspended in 
SDS loading buffer and subjected to SDS-PAGE analysis (10% polyacrylamide gel). 
Phosphorylation of Stat3 was determined by immunoblotting using the specific phospho-Stat3 
(Tyr 705) antibody at a dilution of 1:1,000 (top).  Membranes were stripped and reprobed with 
an antibody to Stat3 to assure equal loading (bottom).  
 
6.1.2. Expression of Stat3 mutants in colorectal carcinoma (CRC) 
cells as a means to study the role of Stat3 in malignant cell 
transformation 
In order to address the possible functional involvement of Stat3 to the malignant 
transformation of colon epithelium cells, various Stat3 derivatives were expressed in the 
colon carcinoma cell line HT-29. The following Stat3 variants were stably introduced into 
HT-29 cells by retroviral infection (cell lines were generated by Frauke Döll and Edith 
Pfitzner, Georg-Speyer-Haus, Frankfurt/Main): Wild type Stat3 (resulting in cell line HT-
29/Stat3), constitutively active Stat3 that had been generated by introduction of a disulfide 
bridge which forces the formation of stable dimers (Bromberg et al., 1999) (resulting in 
cell line HT-29/Stat3 c.a.), and a dominant negative mutant of Stat3 in which the tyrosine 
residue at the amino acid position 705 is replaced with a phenylalanine (resulting in cell 
line HT-29/Stat3 d.n.). This mutation prevents the Tyr 705 phosphorylation of the Stat3 
which is required for its dimerization and nuclear translocation. As the retroviral vector 
encoded GFP, the fraction of cells expressing heterologous Stat3 could be checked by 
FACS analysis for fluorescence and was routinely above 70% (Fig. 11 and E. Pfitzner 
personal communication).  
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Fig. 11: Analysis of Stat3/GFP expression in HT-29/Stat3 cells by fluorescence microscopy. 
Fluorescence of HT-29 cells over-expressing Stat3 was documented using an Axiovert 135M 
(Zeiss) fluorescence microscope at dark field representation (A) or employing a fluorescens-filter 
(BP 546; FT 580; LP 590) (B). Original magnification: 10 x.   
 
 
In this study, expression of Stat3 variants as well as tyrosine phosphorylation in response 
to IL-6 stimulation was analyzed by Western blot using phospho-specific antibodies for 
Stat3 (Fig. 12). The introduction of a wild-type Stat3 cDNA into HT-29 cells led to a 
robust over-expression of the protein in comparison to parental cells. The abundance of 
tyrosine phosphorylated Stat3 in response to incubation with IL-6 was only slightly 
enhanced, probably due to a saturation of the IL-6 receptor system.  
“Stat3 c.a.” and “Stat3 d.n.” were also expressed to higher levels compered to the 
endogenous Stat3 upon retroviral gene transfer. “Stat3 c.a.” was phosphorylated only to a 
limited extent. This last effect may be due to a poor association of “Stat3 c.a.” with the 
phosphorylated gp130 receptor chain and/or to a poor accessibility of the phosphorylation 
site for the Jak kinase. “Stat3 d.n.” completely blocked IL-6-dependent phosphorylation of 
endogenous Stat3. 
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Fig. 12: Expression and activation of heterologous Stat3 variants in HT-29 cells. Western 
blot analysis of tyrosine phosphorylation (top) and expression (bottom) of retrovirally 
introduced Stat3 variants in HT-29 cells. Cells were left untreated (-) or incubated with 20 
ng/ml of IL-6 for 30 min (+). 20 µg of protein from  whole cell extracts was resuspened in 
SDS loading buffer and subjected to SDS-PAGE analysis (10% PAA gel). Phosphorylation of 
Stat3 was determined by immunoblotting using the specific phospho-Stat3 (Tyr 705) antibody 
at a dilution of 1:1,000 (top).  Membranes were stripped and reprobed with an antibody to 
Stat3 to assure equal loading (bottom).   
 
 
6.1.3. Stat3 accelerates the proliferation of colon carcinoma cell line 
HT-29 
Constitutive activation of the Stat3 in a wide variety of cancers raises the question of the 
contribution of this activity to cell proliferation control. To test this possibility, the effect 
of the heterologous Stat3 constructs on the proliferative behavior of HT-29 cells was 
analyzed. Proliferation of HT-29 cells was monitored over a cultivation period of nine days 
(Fig. 13). The presence of IL-6 in the medium resulted in a faster cell proliferation, 
suggesting an involvement of gp130-triggered Jak/Stat3 signaling in growth control (Fig. 
13A). Confirming this notion, (over-) expression of “Stat3 c.a.” and Stat3 led to a profound 
acceleration of cell proliferation, whereas expression of “Stat3 d.n.” resulted in a 
significant decrease in the proliferation rate (Fig. 13B). Infection of HT-29 cells with the 
empty retroviral GFP-vector had no significant effect on cell proliferation (data not 
shown). These results show that Stat3 promotes cell division and proliferation of the colon 
carcinoma cell line HT-29. 
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Fig. 13: Effects of Stat3 activity on HT-29 cell proliferation. A: Proliferation of HT-29 
cells in response to IL-6 stimulation. Samples of 5x104 cells of each cell line were seeded into 
individual wells of 6-well cell culture plates in a volume of 2 ml. After 3, 6, and 9 days, 
aliquots were counted using a Neubauer chamber, and cell numbers were extrapolated to the 
total culture volume. When present, the IL-6 was in the medium at a concentration of 20 
ng/ml throughout the entire cultivation period. The results shown represent the mean of four 
independent experiments. B: Proliferation of HT-29 derivatives expressing constitutively 
active, wild type or dominant negative Stat3 variants in comparison to non-transfected cells. 
The results shown represent four independent experiments. 
 
 
6.1.4. Stat-3 promotes soft agar colony formation of CRC cell lines 
The formation of colonies in soft agar indicates the potential of cells to grow 
independentely of cell anchorage and is a measure of oncogenic cell transformation. To 
examine the effect of Stat3 on transformed growth, HT-29 cells and derivatives (over-
expressing Stat3 and “Stat3 c.a.”) were compared with regard to anchorage-independent 
growth employing a colony formation assay.  
Cells were seeded into 0.6% agar, overlaid with medium and incubated for 2 weeks before 
colonies were counted. Fig. 14 demonstrates that over-expression of Stat3 in HT-29 cells 
significantly increased the number of colonies. A much more pronounced effect was 
induced by “Stat3 c.a.”. These results indicate an influence of Stat3 activity on the 
oncogenically transformed cellular phenotype. 
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Fig. 14: Influence of Stat3 activity on colony 
formation of HT-29 cells in soft agar. Stat3 
derivatives over-expressing Stat3 or “Stat3 c.a.” as 
well as non-transfected HT-29 cells were grown in soft 
agar for two weeks. Colonies formed were visualized 
by staining with MTT (500 µg/ml) (A). In each well, 
colonies in seven view field were counted. The values 
result  from triplicate experiments (B). 
 
 
6.1.5. Stat-3 activity enhances invasiveness of CRC cell lines 
The results concerning the influence of Stat3 on proliferation and colony formation of HT-
29 cells pointed towards enhanced migratory properties of this cell line in dependence of 
Stat3 activity. This was addressed by seeding the cells onto Matrigel® coated filters of 
chemotaxis Boyden chambers and measuring their ability to cross these filters as a measure 
of their invasive behavior in vitro. The basement membrane matrigel is an extract of the 
Englebreth-Holm-Swarm mouse tumor. In most cases, cells capable to penetrate the 
Matrigel layer in vitro are also highly metastatic in vivo (Janiak et al., 1994). Aliquots of 
2x105 cells of HT-29 cells and derivatives over-expressing Stat3 or “Stat3 d.n.”, 
A
B 
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respectively, were seeded onto a layer of Matrigel. After 24 h, the fraction of cells that had 
migrated through the gel and accumulated in a lower compartment was determined. Fig. 
15A shows the invasion profile of tumor cells, expressed as the percentage of invasive 
cells compared to the total number of cells placed in the upper compartment of the 
chamber. With 25% of cells migrated through the Matrigel coated filters, “HT-29/Stat3 
c.a.” cells had the strongest invasive character, followed by Stat3 over-expressing cells 
(15%) and non-transfected HT-29 (7%). Moreover, to test possible stimulatory effects of 
IL-6, an activator of Stat3, on transmigration, cells were suspended in the appropriate 
medium supplemented with 20 ng/ml of IL-6. Presence of IL-6 in the medium (24 h before 
the assay as well as during the assay) resulted in enhanced cell invasiveness of non-
transfected HT-29 cells (2.6-fold) and HT-29/Stat3 (1.4 -fold) (Fig. 15B). The expression 
of “Stat3 d.n.” completely blocked this effect. 
Stat3 activity was found clearly correlated with the cells’ ability to grow in an invasive 
manner.  
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Fig. 15: Cell invasiveness in dependence of Stat3 activation in colon carcinoma cells.  
A: Quantitative evaluation of invasive growth of HT-29 cells and derivates expressing Stat3 
variants. HT-29, HT-29/Stat3 and HT-29/Stat3 c.a. cells were seeded onto MATRIGELTM coated 
membranes. After 24 h, cells which had migrated to the lower compartment of the system were 
counted. Cell invasion was determined as mean number of cells invaded through the MATRIGELTM 
membrane (the rate of the invasion was expressed as the fraction of migrated cells compared to the 
total number of cells placed in the chamber). This assay was repeated four times in triplicates. B: 
Effect of IL-6 on the invasiveness of HT-29 cells and derivatives expressing Stat3 variants. HT-29, 
HT-29/Stat3 and HT-29/Stat3 d.n. were grown on MATRIGELTM in the absence (-) or presence (+) 
of IL-6 (20 ng/ml) 24 h before and during the experiment. The experiment was repeated three times 
and each treatment was performed in triplicate. 
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 6.1.6. Stat3 has transforming effects on the COGA-1 low passage 
number CRC cell line 
To exclude the possibility that the findings described so far are the consequence of specific 
properties of the HT-29 cell line, we studied the influence of Stat3 on the malignant 
properties of another colon carcinoma cell line (COGA-1). This low passage cell line is 
devoid of chromosomal instability (Vécsey-Semjen et al., 2002) and is, thus, a 
homogenous cell culture model which mirrors the tumor situation in vivo particularly well. 
Therefore, effects of Stat3 on proliferation, colony formation in soft-agar as well as 
invasiveness of COGA-1 cells were analyzed. As for HT-29 cells (see above), derivatives 
expressing heterologous wild type Stat3 and constitutively active Stat3 (“Stat3 c.a.”) had 
been generated by retroviral infection (cell lines were obtained from Frauke Döll and Edith 
Pfitzner, Frankfurt/Main). 
As shown in Fig. 16, Stat3 and, to a stronger extent, “Stat3 c.a.” promote proliferation of 
the colon carcinoma cell line COGA-1. A profound stimulating effect of IL-6 on cell 
proliferation of COGA-1 cells was observed. COGA-1 cells over-expressing Stat3 and 
“Stat3 c.a.” formed five to six times more colonies in soft-agar as non-transfected cells. 
Invasiveness of COGA-1 cells over-expressing Stat3 or “Stat3 c.a.” was significantly 
higher compared to control cells. 
These findings suggest an important general role of Stat3 in cell transformation and 
progression in the context of colon cancer. 
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Fig. 16: Effects of Stat3 activity on cell transformation parameters in the low 
passage COGA-1 cell line. A: Proliferation of COGA-1 cells upon IL-6 stimulation. 
The experiment was performed as in Fig. 13 with the following variations: individual 
cultures were started at a cell number of 2x104; cell numbers were determined after a 
cultivation of 3 and 6 days. Four experiments were done independently. IL-6 was 
present in the medium at a concentration of 20 ng/ml throughout the entire cultivation 
period. B: Proliferation of COGA-1 derivatives expressing constitutively active or 
over-expressing Stat3 variants. C: Colony formation of COGA-1 and derivatives in 
soft agar. 104 cells were grown in soft agar for three weeks. Formed colonies were 
stained with MTT and counted. D: in vitro invasion through MATRIGELTM of COGA-1 
lines expressing Stat3 derivatives compared to non-transfected cells. After 24 h, cells 
which migrated to the lower well were counted. This assay was repeated four times in 
triplicates (the results shown represent mean ±SE). 
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 6.2. Elevated expression of a subset of proteinases in colorectal 
tumor biopsies coincides with constitutive activity of Stat3 
 
6.2.1. Stat3 activity in colorectal tumors correlates with expression of 
tumor- associated metalloproteinases MMP-1, -3, -7 and -9. 
The results obtained so far raised the question of how Stat3 enhances the invasiveness of 
colon carcinoma cells. It is logical that the mechanism(s) through which this persistently 
active transcription factor mediates cellular transformation and invasiveness implicate 
activation of specific genes. It is known that proteinases, in particular collagenases, are 
required as key lytic enzymes for the invasion process. Indeed, their inhibition by 
metalloproteinase inhibitors totally prevented the amnion- or matrigel invasion (Reviewed 
in Chambers and Matrisian, 1997). To understand the molecular mechanisms responsible 
for Stat3-mediated tumor invasion we analyzed mRNA from 15 cancer samples using 
human cDNA macroarrays covering 50 different protease probes (Tab. 5; compare 
Material and Methods). Samples of 5 µg total RNA isolated from tumor tissues were used 
to generate Digoxigenin-labelled cDNA, which was subsequently hybridized to the 
membranes.   
All primary CRC samples have previously been tested for Stat3 activity (experiments were 
performed by Florian Corvinus). According to these results, the biopsies were divided in 
groups of high and low Stat3 activity and then tested for expression of tumor-associated 
proteinases by cDNA arrays (examples of raw images in Fig. 17A). In most tumor tissues 
of “Type I“(high Stat3 activity, left-hand side), high expression of invasion-associated 
matrix metalloproteinases MMP-1, MMP-3, MMP-7 and MMP-9 was found. In contrast, 
for “Type II“ specimens (low Stat3 activity, right-hand side), no apparent expression of 
this set of MMPs was observed. The expression of MMPs -1, -3, -7 and -9 in a total of 15 
tumor samples was quantified by densitometric determination of signal intensities on 
cDNA array membranes using the computer program “Aida” (version 3.11, Raytest, 
Straubenhart). To normalize the different exposures, mean signals derived from four 
“housekeeping“mRNAs (GAPDH, ß-actin, ubiquitin, R13α), spotted on the same 
membrane, were set 100% (Fig. 17B). 
These data clearly indicate that tumor-specific expression of four MMPs occurs in 
conjunction with Stat3 activity. 
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Fig. 17: Comparison of protease gene expression in colon carcinoma tumor 
samples with high versus low Stat3 activity using cDNA macroarrays. A: Total 
RNA was isolated from tumor samples with high Stat3 activity (Type I) and with 
low Stat3 activity (Type II). Digoxigenin-labeled cDNA samples were generated 
from each RNA sample and hybridized to two identical human cDNA arrays on 
nylon membranes. Membranes were exposed to X-ray film at room temperature for 
40 min. B: The relative expression levels of MMP-1, -3, -7 and -9 in 15 tumor 
samples were quantified by densitometry and normalized to the respective mean of 
four “housekeeping” control mRNAs (GAPDH, β-actin, ubiquitin and R-13α). 
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6.2.2. Elevated expression of other proteinases and inhibitors of 
proteinases in Stat3-positive tumors.  
Apart from the MMPs discussed in the previous chapter, less pronounced Stat3-related 
differences in expression were also found for other proteinases. mRNAs for Cathepsin B, 
tissue inhibitor of MMP (TIMP)-1, urokinase-type plasminogen activator (uPA), uPA 
receptor (uPAR), plasminogen activator inhibitor (PAI)-1, MMP-11, membrane-type 
MMP-1 (MT1-MMP), a disintegrin-like and metalloproteinase (ADAM)-8 were more 
abundant in “Type I” tumors (Fig. 18). However, expression of most of these proteases 
was so diverse within the respective groups of tumor samples that the correlation with 
Stat3 activity remains disputable. 
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Fig. 18: Comparative expression analysis of proteases in CRC tumor samples 
associated with Stat3 activity to a moderate extent using cDNA macroarrays. The 
relative expression levels of proteinases in 15 tumor samples (seven Stat3 positive “Type I 
“ tumors and eight Stat3 negative “Type II“ tumors) was quantified by densitometry and 
normalised as in Fig. 17.   
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 6.3. Stat3 activity influences expression and enzymatic activity of 
the matrix metalloproteinase -1 (MMP-1) in the HT-29 colon 
carcinoma cell line 
 
6.3.1. Stat-3 activity associated with MMP-1 expression in CRC 
tumors  
In the following, this study focuses on MMP-1 as a possible target gene relevant for the 
influence of Stat3 on cell transformation for several reasons: 
-1) out of all proteases tested, MMP-1 showed the highest expression; 
-2) MMP-1 is the most abundantly expressed MMP degrading type I and III collagen, 
major constituents of the extracellular matrix. 
To confirm the results obtained by cDNA arrays, expression of the endogenous MMP-1 
gene was measured by quantitative real-time PCR. The 18S ribosomal RNA gene was used 
as an endogenous control to normalise for differences in the amount of cDNA employed. 
Data were initially expressed as a threshold cycle (CT), defined as the point at which an 
increase in fluorescence above a baseline signal can first be detected. In contrast to the 
samples with low Stat3 activity, far more MMP-1 mRNA was measured in CRC specimens 
with high Stat3 activity (Fig. 19). 
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Fig. 19: Real-time PCR detection of MMP-1 mRNA 
levels in CRC biopsies of with low and high Stat3 
activity. Total RNA was isolated from tumor samples 
with high Stat3 activity (Type I) and with low Stat3 
activity (Type II). Quantification of MMP-1 mRNA 
levels was measured by real-time RT-PCR. Three 
independent experiments were performed (each run in 
triplicate). Results were normalized and expressed as 
the means ±S.E. Relative MMP-1 expression was 
calculated by arbitrarily setting the expressions from 
samples “Type I” as 1 (100%). 
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6.3.2. MMP-1 expression is co-localised to Stat-3 activity in colorectal 
tumors  
Immunohistochemistry was performed on CRC biopsies to deteremine which cell types 
within the tumors are responsible for the biochemically detected MMP-1 signals, and to 
correlate the respective localisation of Stat3 activity and MMP-1 expression. 
Fig. 20 shows a representative example of intense immunohistochemical MMP-1 staining 
in a colorectal carcinoma of high Stat3 activity (as previously shown by Western blot 
analysis, Florian Corvinus, pers. communication) in comparison to a tumor specimen with 
low Stat3 activity. Strong immunoreactivity of MMP-1 in the carcinoma cells themselves 
was found in all cases of colon carcinoma with high Stat3 activity. MMP-1 was not 
expressed neither in epithelial cells of normal intestinal crypts nor in stromal cells (i.e., 
fibroblasts, inflammatory cells) around the tumor (Fig. 20A). In contrast, expression of 
MMP-1 in tumor cells with low Stat3 activity was not significantly elevated compared to 
non-cancerous epithelial cells (Fig. 20B), in which immunostaining of MMP-1 protein 
was only marginal as evident in mucosal sections of healthy colon tissue (Fig. 20C). 
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Fig. 20: Immunohistochemical staining for MMP-1 in representative, paraffin-embedded 
specimens of primary CRCs and control tissue. Sections of a CRC biopsy with strong Stat3 
activity (A), a specimen with low Stat3 activity (B) and healthy control tissue (C) were treated with 
a specific antibody to MMP-1. Arrows indicate: 1 – de-differentiated tumor cells, 2 – normal 
epithelial cells, 3 – stromal cells. Original magnification in A and B: 20x, in C: 40x.  
 
 
6.3.3. Stat-3 activity in CRC cell lines correlates with the level of 
MMP-1 mRNA 
To address a possible causal connection of Stat3 activity and MMP-1 expression, MMP-1 
gene transcription was examined in the presence or absence of IL-6 in HT-29 cells 
transfected with Stat3 derivatives. The cells were treated with 20 ng of IL-6 for 24 h before 
mRNA levels were measured by real-time quantitative PCR (Fig. 21). Expression of 
heterologous Stat3, and even more pronounced, of “Stat3 c.a.”, increases the level of 
MMP-1 mRNA in HT-29 cells, indicating that Stat3 is involved in the induction of MMP-1 
transcription. This notion is supported by the finding that stimulation by Interleukin-6, a 
Stat3 activator, influences MMP-1 expression in a positive way. 
These results suggest that Stat3 may directly act on the transcription of the MMP-1 gene in 
the colon carcinoma cell line HT-29.  
A2C 
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Fig. 21: Influence of Stat3 expression and IL-6-induced activation on 
the abundance of MMP-1 mRNA in HT-29 cells. Confluent HT-29 cells 
cultured in RPMI 1640 with 10% FCS were treated with IL-6 (20 ng/ml) 
for 24 h. Total cell RNA was isolated, reversely transcribed, and the 
resulting cDNA was used for real-time quantitative RT-PCR with specific 
primers and probes for MMP-1 as described in Material and Methods. 
Three independent experiments were performed (each run in triplicate). 
The results were normalized and expressed as the means ±S.E. Relative 
MMP-1 expression was calculated by arbitrarily setting the expressions 
from samples with “Stat3 c.a.” as 1 (100%). 
 
 
6.3.4. Stat3 activation in CRC cells correlates MMP-1 enzyme activity 
To address in how far real-time PCR data reflected the actual protein expression and 
activity, an immunoassay for activated MMP-1 was employed. Supernatants from HT-29 
cells and Stat3-expressing derivatives were subjected to an ELISA measurement for a 
fluorescing product of catalytically active MMP-1. Non-stimulated HT-29 cells secreted 
only a small amount of active MMP-1. In transfected cells, secreted MMP-1 activity was 
enhanced by heterologously expressed Stat3 (7.6-fold) and “Stat3 c.a.” (8.5-fold) (Fig. 22). 
The activation of Stat3 by IL-6 significantly increased levels of active MMP-1 secreted by 
both non-transfected (5-fold) and Stat3 over-expressing HT-29 cells (2-fold) compared to 
the respective non-stimulated cells. “Stat3 d.n.” totally supressed the increase of 
fluorescence (>99%), and no MMP-1 activation was found even upon IL-6 stimulation. 
These results indicate that Stat3 contributes to the induction of matrix metalloproteinase-1 
activity secreted by HT-29 colon carcinoma cell lines, thereby possibly promoting the 
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degradation of collagen during invasive growth. Moreover, the data issued from the ELISA 
experiment are consistent to the results obtained by real-time PCR (see above). 
  
0
0 , 5
1
1, 5
2
2 , 5
3
En
do
ge
no
us
 A
ct
iv
e 
M
M
P-
1
(n
g/
m
l)
IL-6 + -- +- +-
HT-29 HT-29/
Stat3
HT-29/
Stat3d.n.
HT-29/
Stat3c.a.
En
do
ge
no
us
 A
ct
iv
e 
M
M
P-
1
(n
g/
m
l)
 
Fig. 22: Influence of Stat3 expression and activation by IL-6 on MMP-1 
activity secreted by HT-29 cells. HT-29/Stat3, “Stat3 c.a.” and “Stat3 d.n.” cells 
as well as non-transfected cells were cultured in RPMI 1640 with 10 % FCS. Cells 
were cultured to confluency for 4 d in the presence (+) or absence (-) of 20 ng/ml 
IL-6. Aliquots of the supernatants were used for the determination of MMP-1 
activity as detailed in Material and Methods. This assay was repeated three times 
in duplicate (shown results represent mean ±SE). 
 
 
 
6.3.5. The MMP-1 promoter is regulated by Stat3 in HT-29 CRC cells 
To obtain information about the possible connection between Stat3 and MMP-1 
transcription, the human MMP-1 promoter (Rutter et al., 1997) was analysed for the 
presence of putative Stat recognition sequences and found to contains 14 Stat3 specific 
binding sites of the type GAANNNTTC (Fig. 23).  
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Fig. 23: Putative Stat3 binding sites in the human MMP1-Promoter. The nucleotide 
sequence for the MMP-1 promoter clone is was obtained from the GenBank database (GenBank 
Accession Number AF023338, Rutter et al., 1997). Stat3 recognition elements are boxed, the two 
half sites of the Stat3 binding element are highlighted in red. 
 
     1 cctcacatat ttcaaatcca tctcaaattc acattcacag atgtaagagc tgggaaagga 
    61 cggttttgac agggctgaac tgagctatgg tatgagtagc actcatcccc agaaagtctc 
   121 ttggtttgaa tttccgggaa aaggagctat agctgcaaaa atctgtttca caaatgtgct 
   181 aactataagc attttccaca gtgtttaata aaccatgcag ataagaaaat attattgaca 
   241 aacaaattaa taaaatgctc aaaataatct gatactaaat gcttgtagca tggcatgcaa 
   301 atcaccaaaa ataaatgtgc tatgcttcat ataaaatctc cagtaaggct gggtgtggtg 
   361 gctcacacct ataatcccaa cactctggga ggccgaggtg agagaactgc ttgaggccag 
   421 gagtttgaga ctagcctggc caacatagtg agacctcatc tctacaaaaa atcttaaaaa 
   481 tcagtgggac atggtggtgc acatctgtag ttctagctac ttgggagtct gaggcaggaa 
   541 gattgcttaa gcccaagagt ttgaggtccc tacactccag cctaagcgac agagggagac 
   601 cttgtctcta aataaataaa ttagttaatt gaatgtccag tcagttgata tatccaaatt 
   661 cttcccatgg taattttaaa aactttagtc ttaggagagt aaaagtcatg gacataagac 
   721 ttcttataaa caactcagcc taatgagaaa tagaccctgt atttaagtgt catttaagta 
   781 tctatttctt cattgatcta ttcatttatt aactcctgta acaatcattt gcagacacct 
   841 actatgttga ggtagtataa actataaatt caacaagttt gataagggaa ataagagaga 
   901 ttgagtgaca gcttgaaggg gaggattctt tcaggcctgt gggaccgggt ggtggcatgg 
   961 agacattatt gtggacttga gggagttaat gtgacagtcc tcgtgtctcc agacactttc 
  1021 tctctgttag ggaagcaaga tttctatccc cagagtatgt atgtgttatg tctggactgc 
  1081 agtggcacag aactgtgttc aacgagtgac taccgctctg ctgtgtgccc tgggacttgg 
  1141 ggttaattga tcaatcattt ctatccagaa ggtaaccatg aggactgacg gaaccagtgt 
  1201 gtaccaagtg tctgttaagt gtctggtcaa tggttatcca taaagctact gcatggccat 
  1261 atgtaggaag aatacacacc gtgagcaaat ttttcccacg tgtaactctc acaacaaaat 
  1321 agcattaaat acttaatgtt tctggctaaa gaccatttca agacttgcag gacaaaaaaa 
  1381 tagaaaaaat atctgacact caaatggagt tacaaaatta aaacggctga attccccagc 
  1441 ataaaaaaat atgaagcaag attgaaattt caagactaag tttaatatgg aaaaatacaa 
  1501 atatgtttga ggcctttcac agagcagcca gcatgaagca accaagaaaa ccacggaaat 
  1561 aatctggctg cctggaaata gtccggagtc agctgacaca gccacacgag agccctctta 
  1621 tgcttgtcat aaggggtaaa ggaataattt cagaaaatta catttaaaag agaattatgg 
  1681 gggaagaaga tgctcccaga ggaaacaaat agtatggatg tgaagagcaa atacaacttt 
  1741 aacatgtttt gaacttcttg gaaactatgc taagtttagg cattgctagg atttggtatg 
  1801 atttaatccc cagctttctg ttctaaattt ttgttttctt ttttactctc aaataaatca 
  1861 tatgctagca ccagctgcaa agttacatat gttgtattag acgatcttcc atgaatacct 
  1921 aactggaaat tccaagattc agggccatgt gaatctaggc tggctgctta accaaaactt 
  1981 aatttaattt ttttcgttta ttttaggaaa aaaaattaac gaaaagatgt ttcaagcaac 
  2041 cagtttccaa tccacgtcag caactatgac atttaatgaa acactgtgag catttagcat 
  2101 gagagctctg gactcagatg cagggagctt tgctagagaa gggaggaaaa agcaggcatg 
  2161 atgtggcggg ttgtggggga ctccaaggct ctatttccaa cttccatcag agaacttctg 
  2221 ttttcacctg gttttcaaat ttgctttcca aaagggattt tgtttaagta aaggatacag 
  2281 aggtttataa aagtttgaaa acttctacat tgcaggatgt gcaggctctt gccagatggg 
  2341 acagtgtatg agactcttcc agggtgacgt cttaggcaat ttcctgtcca atcacagatg 
  2401 gtcacatgct gctttcctga gttaacctat taactcaccc ttgtttccca ggcctcagtg 
  2461 gagctaggct tgtcacgtct tcacagtgac tagattccct cacagtcgag tatatctgcc 
  2521 actccttgac ttttaaaaca tagtctatgt tcaccctcta atatgaagag cccctttcac 
  2581 tattttcttt gtctgtgctg gagtcacttc agtggcaagt gttctttggt ctctgccgca 
  2641 ccctccctct gatgcctctg agaagaggat ttccttttcg tgagaatgtc ttcccattct 
  2701 tcttaccctc ttgaactcac atgttatgcc acttagatga ggaaattgta gttaaataat 
  2761 tagaaagata tgacttatct caaatcaatc caagatatac tgaagtattg tttatgagta 
  2821 agatatcagt cttgacgcag aaagaaaaca ggaatccata aggggaggaa agtgttgaaa 
  2881 agcaaacctg atacagtggg aaaggtggga gacaccataa ggtgctgaag tgataaaaca 
  2941 ggccagtgtt tctccactgt atgttttcaa taaatgcttc caaggaagga gagtggggca 
  3001 tgagtagggg agctacagag ataaaccaac ttttcttacc aggaatgcta cagatagcac 
  3061 tggtgacacc ggtcaccagt acccaagaca atttaatgtg gaacataagt acaggaatac 
  3121 acatctttca ttacagagcc atgtatttat tttaatgggc aggagatgct aaataagatc 
  3181 ttttgaatgg aggaatgcat aaatatatga atgaatgcat acatgaaaga ataaataaat 
  3241 gctgcctagc accaaggagc gaagatagac tcatatcaag ggaaacaagt atgattaaaa 
  3301 ataagacccc agagtcacgc tcagtctctt tccagccttt tcatcatccg gtacattcag 
  3361 acaagtttca gggaaggatc ctatttgtcc catgataatg atgggcaagg ggtggggagt 
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  3421 tatctcatac tccgcctgtg gatgaggggt cttctcaggt aaggctctta aatcctaggc 
  3481 ctgagtaaat tttttcaaat tttattttag acagggtccc tctctgttgc ctaggctgga 
  3541 gtgcagcggc acaatcacag ctcaatgcag cctcaacctc ccaggcccaa gtgatcctcc 
  3601 cacctcagcc tcttcagtga ctaggactac aggtgcatga ctccatgctt ggctaacttt 
  3661 aaaaaatgtt tgtttgtttg tttgtttttt acagagatgg ggtctcacca tgttgcccag 
  3721 gctgatcttg aactcctggg ctcaagtgat tcccctgcct cggcctcctg aaattctggg 
  3781 attataggct tgagccacca tgcctggctc tgagtaaaga ttaagggaag ccatggtgct 
  3841 atcgcaatag ggtaccaggc agcttaacaa aggcagaagg gaacctcaga gaaccccgaa 
  3901 gagccaccgt aaagtgagtg ctgggggagc tgaacttcag tcagtacagg agccgaacag 
  3961 ccatcaggtg cgcagtgtta gtaattccac cctctgccct gggagcaagg tgtgtggaga 
  4021 aacctgtagc actttatgac catcagaacc agcctttttc aaaaagacca tggagtactc 
  4081 tttgacctgt gtatataaca agaacctttc tcaaatagga aagaaatgaa ttggagaaaa 
  4141 ccactgttta catggcagag tgtgtctcct tcgcacacat cttgtttgaa gttaatcatg 
  4201 acattgcaac accaagtgat tccaaataat ctgctaggag tcaccatttc taatgattgc 
  4261 ctagtctatt catagctaat caagaggatg ttataaagca tgagtcagac acctctggct 
  4321 ttctggaagg gcaaggactc tatatataca gagggagctt cctagctggg atattggagc 
  4381 agcaagaggc tgggaagcca tcacttacct tgcactgaga aagaagacaa aggccagt 
 
  
To further analyze the ability of Stat3 to directly influence the induction of the promoter 
activity of hMMP-1 a luciferase reporter construct driven by 4.3 kb of the human MMP-1 
promoter (the sequence shown in Fig. 23) was employed. Parental HT-29 cells as well as 
derivatives over-expressing Stat3 and “Stat3 c.a.” were transiently transfected with this 
construct and subsequently treated with IL-6. Luciferase activity measured 22 h after 
transfection was normalized by cotransfecting of HT-29 cells with a pRL-TK Renilla 
luciferase vector as described in Material and Methods. 
Rutter et al. (1998) described that the incidence of the 2G allele at the position -1607 bp 
(see Materials and Methods, Fig. 3) in the human (h) MMP-1 promoter possibly is 
correlated with aggressive tumors.  
Therefore, both the 1G and 2G variant of the hMMP-1 promoter were included in the tests 
for Stat3 influence on promoter activity. HT-29 parental cells as well as HT-29 cells over-
expressing Stat3 were transiently transfected in parallel with luciferase reporter constructs 
driven by MMP-1 promoter with either one or two G nucleotides at position -1607 and 
optionally stimulated with IL-6. Fig. 24A shows that a significant increase in transcription 
(ranging from 2-3-fold) was observed with the 2 G promoter construct compared to the 1 G 
promoter construct. IL-6 induced a similar relative effect (2.5-fold induction) on 
transcription with both 1 G and 2 G constructs in HT-29/Stat3 cells. 
These data suggested that the presence of 2 G nucleotides at position -1607 in the MMP-1 
promoter is important for transcriptional regulation of the hMMP-1 promoter by Stat3. For 
this reason, in the next experiments, the 2 G version of the hMMP-1 luciferase reporter 
gene construct was used.  
To further investigate the role of Stat3 for MMP-1 transcription, HT-29 derivatives over-
expressing Stat3 and “Stat3 c.a.” were included in the study (Fig. 24B). In both cell lines, a 
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clear increase in transcription of the hMMP-1 luciferase reporter construct was observed 
compared to non-transfected cells. IL-6 treatment strongly induced the promoter activity of 
the hMMP-1 promoter in HT-29 cells as well as in cells over-expressing Stat3 (Fig. 24C). 
The results demonstrate that Stat3 has an immediate effect on transcriptional activity of the 
MMP-1 promoter in HT-29 cells. They underscore a potential functional relation of Stat3 
activity and expression of proteases relevant for tumor cell malignancy. 
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Fig. 24: Effects of Stat3 activity on transcriptional activitation of the human MMP-1 
promoter.  
A: Effects of the single nucleotide polymorphism (SNP) at -1607 bp of the hMMP-1 promoter on 
Stat3-mediated promoter activity in HT-29 cells. HT-29 cells or HT-29 cells stably over-expressing 
Stat3 were transiently transfected with 1 µg of the 4,3 kb human MMP-1 1G- (left) or 2Gs (right) 
luciferase reporter plasmid together with 0.1 µg of the pRL-TK Renilla luciferase vector as an 
internal control. Cells were optionally treated (overnight) with 20 ng/ml IL-6 before luciferase 
activity was measured. The results were normalized to renilla activity. B: Induction of human 
MMP-1 promoter activity by means of stable transfection of HT-29 cells with Stat3 or the “Stat3 
c.a.” mutant. The experiment was performed as described under A. Three independent 
transfections, each run in triplicate, were performed and the results were normalized to renilla 
activity and expressed as the means ±S.E. C: Transcriptional activation of the hMMP-1luci 
reporter gene in HT-29 cells following stimulation with IL-6. Non-transfected HT-29 and HT-
29/Stat3 cells were transiently transfected with hMMP-1luci 2G reporter plasmid and stimulated 
with IL-6 as described above.   
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6.3.6. Constitutive Stat3 activity and MMP-1 expression are 
correlated in tumors derived from a colon carcinoma cell line 
It was previously shown that the constitutively active state of Stat3 in colon carcinoma 
cells is not lost inevitably by cultivation, and can be restored by injecting tumor cells into 
mice (Corvinus et al., 2004). To analyze the differences between colon carcinoma cells in 
culture and in the tumor context with regard to Stat3 activity and MMP-1 abundance, the 
xenograft tumors derived from HT-29 cells (Corvinus et al., 2004) were subjected to the 
analysis of MMP-1 expression by immunohistochemistry. A specific antibody for MMP-1 
revealed high expression of the protease in the cytoplasm of tumor cells (Fig. 25A). To 
approach the mechanisms underlying MMP-1 expression in colon carcinoma cells, MMP-1 
mRNA production in HT-29 cells negative for Stat3 activity and Stat3-positive xenograft 
tumor tissue was compared by real-time RT-PCR. HT-29 colon carcinoma cells showed 
low expression of MMP-1 mRNA. In contrast, expression of MMP-1 mRNA in HT-29 
xenograft tumor was much higher (Fig. 25B). Taken together, MMP-1 expression parallels 
the activity of Stat3. 
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Fig. 25: Comparison of MMP-1 expression in HT-29 xenograft 
tumors and HT-29 cells grown in culture. A: Histological 
examination of a HT-29-derived xenograft tumor for MMP-1 
expression. Sections from a representative tumor induced by injection 
of HT-29 cells into nude mice were reacted with an antibody specific 
for MMP-1. Arrows indicate region of intense MMP-1 staining. B: 
Expression of MMP-1 mRNA in HT-29 cells and xenograft tumors. 
Total RNA was harvested from confluent HT-29 cells or xenograft 
tumors and MMP-1 mRNA levels were measured by quantitative real-
time PCR. Three independent experiments, each run in triplicate, were 
performed, and the results were normalized and expressed as means 
±S.E. Relative MMP-1 expression was calculated by arbitrarily setting 
the expression in samples from xenograft tumors as 1 (100%). 
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6.4. Evidence for an autocrine activation loop driving Stat3 
activity and concomitant MMP-1 expression in colon 
carcinoma cells 
 
6.4.1. Non-adhesive growth of colon carcinoma cells induces Stat3 
activity via an autocrine loop  
The results described so far show that Stat3 activity directly influences malignant cell 
behavior and expression and enzymatic activity of MMP-1 in the colon carcinoma cell line 
HT-29. Because there is no significant Stat3 activation in HT-29 cells in culture, but arises 
upon implantation into mice, experiments presented in the following address potential 
mechanisms of Stat3 activation in xenograft tumors. To this aim, growth conditions were 
provided that would more closely resemble to the tissue environment than standard cell 
culture. It was observed that HT-29 cells cultivated on the non-coated plastic surface of 
Petri dishes displayed a more de-differentiated appearance compared to cells grown in 
regular cell culture flasks, like rounding-up, detachment and formation of clusters in 
suspension (Fig. 26A). It was tested if these morphological changes coincided with altered 
Stat3 activation. Notably, cells growing on non-coated surfaces showed high Stat3 activity 
in non-stimulated HT-29 cells and in HT-29 cells over-expressing Stat3 with regard to 
tyrosine phoshorylation (Fig. 26B). The effect was not evident in cells transfected with 
dominant negative Stat3. This finding was in opposition with the situation observed with 
cells grown in regular culture flasks (compare Fig. 10 and 12).  
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Fig. 26: Comparison of growth behavior and Stat3 activity in HT-29 cells cultivated 
on coated and non-coated surfaces. A: Growth characteristics of HT-29 cells cultivated 
on regular tissue culture plasticware (“t.c.”) and on non-coated surfaces (“non-coated”). 
B: Western blot analysis of tyrosine phosphorylation (top) and expression (bottom) of 
endogenous, constitutively active (“c.a.”) and dominant negative (“d.n.”) Stat3 variants in 
HT-29-derived cell lines. Cells were grown for 4 days. They were then lysed and probed 
with specific antibody for phosphorylated Stat3 (top) and Stat3 (bottom), respectively. 
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Next, it was addressed whether the Stat3 activation in cells grown in contact with non-
coated surfaces may derive from the release of a Stat3 activating factor acting via an 
autocrine/paracrine mechanism. To test this possibility, conditioned medium from HT-29 
cells as well as from HT-29 cells over-expressing Stat3, grown on non-coated plastic 
material for 3 days, was used to cultivate a new batch of cells in regular culture flasks. The 
Stat3 activity status was determined after 30 min (Fig. 27). Interestingly, exposure of cells 
to conditioned medium induced high Stat3 tyrosine phosphorylation in parental cells and 
in the derivative over-expressing Stat3. Conditioned medium from HT-29/Stat3 cells had a 
stronger effect than medium from parental cells, indicating that Stat3 activity is directly 
related to the production of the activating factor. This notion is supported by the 
observation that expression of “Stat3 d.n.” blocked the secretion of stimulating activity 
from cells grown on non-coated surface. These findings strongly indicate the existence of 
a secretory factor from HT-29 cells, which is capable of inducing Stat3 tyrosine 
phosphorylation through an autocrine pathway under conditions promoting cellular de-
differentiation. 
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Fig. 27: Analysis of Stat3 activating properties of culture medium 
conditioned by HT-29 cells grown on non-coated surfaces. A: Left-
hand side: HT-29 cells were grown for 4 days on tissue culture (t.c.) or 
non-coated plastic material. Right-hand side: cells were grown for 30 min 
on tissue culture plastic surface in medium conditioned by the indicated 
cell lines grown on non-coated surface. Conditioned medium was obtained 
by centrifugation of cells and subsequent sterile filtration of the 
supernatant. Cells were harvested after treatment, lysed and subjected to 
Western blot analysis with a specific antibody for phosphorylated Stat3. 
Blots were reprobed with anti-Stat3. B: Same analysis for HT-29 cells 
over-expressing Stat3. 
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6.4.2. Non-adhesive growth of HT-29 colon carcinoma cells 
enhances expression of the MMP-1 gene 
In order to examine the effect of the non-adhesive growth of HT-29 cells on the expression 
pattern of MMP-1, the level of MMP-1 mRNA was measured by real-time quantitative 
PCR. HT-29 cells were incubated on tissue cell culture flasks or on microbiological Petri 
dishes for 4 days in RPMI 1640 before isolation of total RNA. It was found (Fig. 28) that 
the MMP-1 mRNA copy number in HT-29 and HT-29/Stat3 cells from the Petri dishes was 
significantly higher than the one from cells growing in regular flasks (4-fold and 3-fold, 
respectively). These results corroborate previous findings, i.e. MMP-1 expression is in 
correlation with the Stat3 activity in HT-29 cells. 
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Fig. 28: Influence of growth conditions of HT-29 derivatives on 
MMP-1 expression. HT-29- and HT-29/Stat3 cells were grown for 
4 days on regular tissue culture plasticware (“t.c.”) or on non-
coated surfaces. The total RNA was isolated and MMP-1 mRNA 
levels were measured by quantitative real-time RT-PCR. Three 
independent experiments, each run in triplicate, were performed. 
Results were normalized and expressed as the means ±S.E. 
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 6.4.3. Non-adhesive cultivation of HT-29 cells induces the secretion 
of chemokines into the growth medium 
To identify potential autocrine/paracrine factor(s) responsible for Stat3 stimulation in HT-
29 cells, cytokines and growth factors were screened for specific appearance in the Stat3-
activating conditioned medium. Abundance of 79 different factors were compared in 
conditioned media from HT-29 cells grown in regular cell culture flasks and on the non-
coated plastic surface of Petri dishes using a commercial human cytokine array (Tebu-
Bio). Membranes immobilized with 79 capture antibodies specific for cytokine and growth 
factors were exposed in parallel to the two media. Binding of specific antigens was 
subsequently detected by a mixture of detection antibodies. 
In the growth medium of the colon carcinoma cells cultivated on non-coated plastic 
surface, elevated abundance of six proteins was identified in comparison to control 
medium: monocyte chemotactic protein (MCP)-1, angiogenin (Ang), interferon gamma 
inducible protein (IP)–10, IL-1α, macrophage inflammatory proteins (MIP)-1δ and -3α 
(Fig. 29A and B). Surprisingly, all these proteins belong to groups of chemokins taking 
part in inflammatory processes. Two of them were described as important factors in tumor 
formation (angiogenin and MCP-1), for one of these proteins (MCP-1), an inducibility by 
Stat3 has been reported (Kim et al., 2002, also see Discussion). The cytokine arrays 
showed also that the abundance of IL-10, oncostatin M (OSM), growth regulated oncogene 
(GRO), macrophage colony stimulating factor (M-CSF) and MIP-1ß was reduced in the 
medium from the HT-29 cells grown on non-coated surface (Fig. 29C). Further studies are 
required to evaluate the significance of these findings.   
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Fig. 29: Comparative analysis of the abundance of cytokines and growth factors in 
conditioned medium from cells grown on coated and non-coated surfaces. A: Simultaneous 
detection of multiple cytokines and growth factors using a protein array. Conditioned media issued 
from HT-29 cells growth in regular cell culture flasks (left) and on non-coated plastic surface of 
Petri dishes (right) were incubated with cytokine array membranes. The membranes were then 
incubated with a combination of multiple biotin-conjugated antibodies to cytokines. Signals were 
visualized by enhanced chemiluminescence (compare Materials and Methods). B: Relative 
expression levels of factors up-regulated in conditioned medium issued from HT-29 cells growth on 
Petri dishes in comparison to control medium. The intensities of signals were quantified by 
densitometric determination. In order to normalize the different exposures, the mean signals 
derived from six positive controls were set 100 % percent. C: Relative expression levels of factors 
down-regulated in conditioned medium issued from HT-29 cells growth on Petri dishes in 
comparison to control medium. The levels were normalized to the   mean of six positive controls 
which was set 100%.   
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 7. DISCUSSION 
 
Carcinogenesis is a process dependent upon the decrease of tumor suppressor and increase 
of oncoprotein activity. During the multistep process of tumorigenesis, cells lose their 
normal ability to sense and repair DNA damage and to regulate cell cycle progression and 
apoptosis (Brinckerhoff et al., 2000). Simultaneously, they acquire abnormal patterns of 
growth factor signalling, angiogenesis, and invasive growth. 
Tumor invasion and metastatic processes entail the loss of cell adhesion, degradation of the 
extracellular matrix as well as the basement membrane, and concomitant induction of cell 
movement (Liotta and Kohn, 1990). Various molecules promoting motility, such as growth 
factors and proteases, have been implicated in these processes. Tumor cells may display 
high constitutive expression of the matrix metalloproteinases (MMPs), even in the apparent 
absence of external stimuli. What mechanisms drive this expression? One possibility is that 
it results from errors in the regulation of signal transduction pathways targeted to the 
collagenase/MMP promoters (Mengshol et al., 2000; Dechow et al., 2004). This work 
provides evidence for a novel connection between erroneous signal transduction and 
protease expression in colorectal tumor cells via the signal transducer and activator of 
transcription Stat3. 
While the STATs are not known to contribute directly to cell cycle checkpoint regulation 
or DNA repair, they contribute to tumorigenesis through their intimate connection to 
growth factor signalling, apoptosis, and angiogenesis. In addition, because these molecules 
play key roles in immune responses, defective STAT signalling can favor tumor 
development by compromising immune surveillance (Bromberg, 2002).  
 
Stat3 is persistently activated in a large fraction of primary colon cancers as shown both 
by biochemical and immunohistochemical analyses (Corvinus et al., 2004). The over-
expression of p-Stat3 is correlated with clinical stage and nodal metastasis in colorectal 
cancer (Ma et al., 2003). However, mutations in the Stat3 gene have not been identified in 
these cancers; hence, it remained to be determined how endogenous Stat3 is constitutively 
activated. The research presented here suggests that Stat3 activity in colorectal carcinoma 
(CRC) can be the result of not only paracrine, but also autocrine stimulation mechanisms. 
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This study elucidates the role of Stat3 activity in the progression of colorectal cancer. It 
was demonstrated in two different cell models that Stat3 promotes proliferative processes, 
and cellular transformation which can be tested by anchorage-independent growth in soft 
agar. The results showed that expression of dominant negative mutant Stat3 blocked IL-6-
induced Stat3 activity and abolished the transformation response in colorectal carcinoma 
cells. Thus, the activated Stat3 molecule can independently mediate cellular transformation 
of these cells. The effect has also been observed in other transformed cell types, e.g., 
glioblastoma cells (Rahaman et al., 2002) and squamous epithelial cells (Grandis et al., 
1998). Fittingly, inhibition of Stat3 activation by the januskinase (Jak) pathway (AG 490) 
leads to decreased proliferation and survival potential of cancer cells (e.g., Sriuranpong et 
al., 2003). Activation of Stat3 has been shown to target Cyclin D1, c-Myc, and Bcl-x, all of 
which are mediators of proliferation and antiapoptosis. Blocking constitutive Stat3 
expression results in growth inhibition and apoptosis of Stat3-positive tumor cells in vitro 
and in vivo (Turkson and Jove, 2000). For the first time, Bromberg et al. (1999) have 
demonstrated anchorage - independent growth of fibroblasts transfected with constitutively 
active Stat3 in soft agar, and subsequent forming of tumors from these cells in nude mice. 
Similar effects have also been demonstrated by Uttamsingh et al. (2003) in embryo 
fibroblasts. The results of this work indicate that Stat3 can mediate oncogenic 
transformation not only of fibroblasts, but also of many others types of cells, including 
colorectal epithelial cells. 
Moreover, not only does constitutive activation of Stat3 induce cellular transformation of 
colon cancer cells, but it can also enhance tumor cell motility and invasiveness. These 
results confirm those reported in another study in which the invasion of diverse human 
cancer cell lines and human dermal microvascular endothelial cells through Matrigel was 
found to be increased with Stat3 activation and suppressed by Stat3 dominant negative 
(“Stat3 d.n.”) mutants (Niu et al., 2002; Yahata et al., 2003). Collectively, these results 
underscore the importance of this Stat3 pathway in the development of an invasive 
phenotype.  
The mechanism of transformation by Stat3 is thought to be through the genes it 
transcriptionally regulates. Transcriptional regulation of genes by activated Stat3 is likely 
to be dependent upon the cellular context and thus the mechanism of transformation. 
Although there is some information about mechamisms of Stat3-driven proliferation, much 
less is known about transcriptional regulation of genes responsible for other aspects of 
malignancy. For example, it has been shown that HGF, a Stat3 activator, induced 
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invasiveness of the CaCo-2 human colon cancer cell line, and HGF stimulation is 
associated with increased production of MMP-1, -2 and -9. In contrast, anti-HGF 
antibodies inhibited protease production as well as cell invasion (Kermorgant et al., 2001).  
In line with this, the correlation between Stat3 activity and expression of tumor-associated 
proteinases was studied in this work. This study focused on MMP-1 as possibly relevant to 
Stat3-mediated transformation because its expression was the highest out of all tested 
proteases. The prognostic significance of MMP-1 expression in colorectal cancer has been 
reported. High levels of MMP-1 expression have been correlated with metastatic spread of 
tumors and poor prognosis of colorectal cancer (Curran and Murray, 1999; Shiozawa et al., 
2000; Horiuchi et al., 2003). This study shows that up-regulation of MMP-1 mRNA is 
dependent upon Stat3 acitivity, as determined by real-time quantitative PCR. The results 
suggest that MMP-1 is expressed neither in colorectal tumors with low Stat3 activity nor in 
HT-29 cells. In contrast, expression of MMP-1 mRNA in corresponding tumors with a 
high Stat3 activity and in Stat3 transfected cells was clearly elevated. One of the major 
questions that comes up in assessing mRNA copy numbers of a gene is the relative 
association with respective protein expression in a specimen. The mRNA copy number of a 
gene does not always correlate with the expression of protein product because of the 
variant post-transcription events, such as mRNA modification, translation efficacy, half-
life of the mRNA, translation modification, and protein turnover in the cell (Takeuchi et 
al., 2003). Results presented here demonstrate that MMP-1 mRNA copy number detected 
by real-time quantitative RT-PCR correlated well with MMP-1 protein expression. It is 
likely that expression as shown by immunohistological staining of tumor samples reflects 
MMP-1 activity, although the actual enzymatic activity could only be tested in colorectal 
carcinoma cell lines. Immunohistological methods showed that primary colorectal 
carcinoma (CRC) tumors, exhibiting a more intense Stat3 activity, demonstrated a 
remarkable increase in MMP-1 staining intensity, relative to primary CRC without Stat3 
activity. These results were confirmed by ELISA for MMP-1 activity in supernatants of 
Stat3 transfected cells. Moreover, IL-6 stimulation of Stat3 in HT-29 cells was shown to 
enhance MMP-1 mRNA expression as well as MMP-1 endogenous activity. Future work 
will include tissue co-localisation of Stat3 and MMP-1 in tumor samples, directly tested by 
simultaneous immunohistological staining of both proteins. It would be very interesting to 
investigate whether elevated Stat3 activity and MMP-1 expression also coincides in other 
malignant tumors. 
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One of the intriguing questions concerning MMP-1 expression is that of the cell type 
producing this enzyme within tumor tissue. This study showed that MMP-1 is localized in 
colon carcinoma cells themselves, but is not found in stromal cells of tumors or in normal 
mucosal tissue specimens. These results corroborate previous findings (Nomura et al., 
1996; Yamashita et al., 2001) and suggest that MMP-1 expression by the carcinoma cells 
themselves is one of the important factors affecting local tumor invasion and metastasis of 
colorectal cancer.  
The enzymatic activity of MMPs was formerly considered to be specifically inhibited by 
tissue inhibitor of metalloproteinases (TIMPs). However, a recent study has shown that 
high levels of TIMP-1 and TIMP-2 are associated with aggressive cancers (Curran and 
Murray, 1999; Baker et al., 2000). Interestingly, in this experiment cDNA arrays revealed 
up-regulation of TIMP-1 mRNA in Stat3-positive samples from colorectal carcinoma, as 
compared to Stat3-negative tumors.  
These results demonstrate that the Stat3 pathway not only plays an important role in 
colorectal carcinoma proliferation and transformation, but is also a driving force behind 
over-expression and elevated activity of MMP-1 in HT-29 cells. Thus, constitutive 
activation of this pathway may allow colon carcinoma cells (at least in certain situations) 
to mutate into an invasive phenotype, thereby facilitating metastasis. Involvement of Stat3 
in invasiveness has also been described for other types of a cancer. As discussed by Yu et 
al. (2002), Stat3 activation is required for the progression of multistage carcinogenesis of 
mouse skin epithelial cells. Both basal and IL-6 induced expression of MMP-1 and MMP-
3 were inhibited by a dominant-negative mutant of Stat3. In another study, blocking of 
endogenous gp130 signalling towards Stat3 in breast cancer cell lines by a dominant-
negative gp130 protein resulted in inhibition of invasion and metastasis of breast cancer 
cells in a nude mouse model (Selander et al., 2004). In renal cell carcinoma a high 
frequency of Stat3 activation was associated with metastatic disease. A high level of p-
Stat3 was a significant indicator of a poor prognosis (Horiguchi et al., 2002). Several 
studies indicate that Stat3 promotes angiogenesis, growth, and metastasis of human 
pancreatic cancer by directly regulating Vascular Endothelial Growth Factor (VEGF) 
expression (Wei et al., 2003).  
 
One purpose of this work was to reveal a direct connection between Stat3 and ММP-1. 
The promoter region of the MMP-1 gene contains various transcription factor binding sites 
including several proximal activator protein–1 (AP-1) and PEA-3 sites (which bind 
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members of the Fos and Jun family of transcription factors), STAT binding sites, cognate 
element for GATA binding factors, and heat shock factors. AP-1 is regulated by mitogen-
activated protein kinase (MAPKs) and is a pivotal transcription factor that regulates 
cytokine production and expression of MMPs (Whitmarsh and Davis, 1996; Brauchle et 
al., 2000; Cho et al., 2000), whereas STAT proteins are frequently involved in mediating 
cytokine-induced intracellular signals leading to expression of inflammatory molecules, 
including MMPs (Kisseleva et al., 2002). The relative effect of AP-1 and STAT proteins 
in MMP expression varies depending upon cell type, stimulus and the MMP being studied. 
For example, a specific inhibitor of Jak3, which impairs Stat3 activation, showed almost 
100% inhibition of MMP-1 and MMP-3 mRNA induction and protein expression levels in 
human chondrocytes. However, inhibition of extracellular signal-regulated kinases (Erk) 
1/2 in human chondrocytes had little effect on the expression of MMP-1 (Behera et al., 
2004). Li et al. (2001) demonstrated that Jak3-specific inhibitor in primary and human 
chondrocytes blocked oncostatin M (OSM) - stimulated Stat1 tyrosine phosphorylation, 
DNA-binding activity of Stat1, as well as MMP-1, -3 and -13 expression. In contrast, a 
Jak2-specific inhibitor, AG 490, had no impact on these events. 
It has been demonstrated that Stat3 plays an important role in FGF-1–induced matrilysin 
(MMP-7) expression. Transient transfection with dominant negative Stat3 inhibited FGF-
1–induced transactivation of the matrilysin promoter. The 1.2-kb region of the human 
matrilysin promoter contains a number of cytokine inducible SH2-containing protein 
(CIS) elements that are known to bind Stat3 (Udayakumar et al., 2002). It was recently 
shown that tyrosine-phosphorylated Stat3 is causally related to MMP-9 promoter activity 
(Dechow et al., 2004). Moreover, a high-affinity Stat3-binding element was identified in 
the MMP-2 promoter. Transfection of constitutively activated Stat3 into poorly metastatic 
C23 melanoma tumor cells directly activated the MMP-2 promoter, whereas the 
expression of a dominant-negative Stat3 in highly metastatic C4 tumor cells inhibited the 
MMP-2 promoter (Xie et al., 2004).  
This work shows that Stat3 directly up-regulates the expression of MMP-1 in HT-29 
colorectal cancer cells. The MMP-1 promoter contains fourteen putative Stat3-binding 
sites (for the DNA binding specificity for Stat3 see Ehret et al., 2001). An MMP-1 
promoter luciferase construct was directly induced at least 3-fold by “Stat3 c.a.” when 
transfected into HT-29 cells.  
The level of MMP-1 expression, and consequentially its potential to mediate connective 
tissue degradation and tumor progression, can be influenced by a genetic variation in the 
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MMP-1 promoter. This variation is a single nucleotide polymorphism (SNP) located at-
1607 bp, where an insertion of a guanine base (G) creates the sequence, 5 '-GGAT-3 ', the 
core binding site for members of the Ets family of transcription factors. Genotyping of 100 
normal individuals indicated that the distribution of this SNP in the normal population is 
approximately: 30% - 1G homozygous; 30% - 2G homozygous; and 40% - 1G/2G 
heterozygous. However, in tumor cells cultured in vitro, the incidence of the 2G allel rises 
to 62%, supporting the hypothesis that there is a correlation with aggressive tumors. This 
in vitro correlation has been upheld in vivo in studies of ovarian and endometrial 
carcinomas. In both studies, the patients had a significantly higher incidence of the 2G allel 
compared with non-cancer controls. Furthermore, patients with the 2G allel expressed 
higher levels of MMP-1 protein (Reviewed in Brinckerhoff et al., 2000). These data have 
formed the basis for experiment with 1G- and 2G- MMP-1 promoters in this work. The 
results showing that an intact Ets binding site enhances Stat3-driven promoter activity 
suggest an additive contribution of Ets and Stat3 to MMP-1 transcription.  
It will be interesting to gain more precise understanding of the contribution of the different 
transcription factors involved in the regulation of the MMP-1 promoter, by applying 
methods, like Electrophoretic Mobility Shift Assays (EMSA) and mutational analysis. 
Considering the substrate specificity of MMPs for extracellular matrix components, the 
involvement of Stat3 in the up-regulation of MMP-1 expression is of importance. Type I 
and type III collagens are the main structural components of the stroma in the 
gastrointestinal tract. Degradation of these structural components is required for further 
invasion, and such degradation is due mainly to the action of MMP-1. Indeed, increased 
collagenolytic activity against type I and type III collagens in cancer tissue extracts is 
reportedly associated with deeper invasion of colorectal cancer (Horiuchi et al., 2003). It is 
important to mention that in the context of this work the promoters of other MMP family 
members, over-expressed in p-Stat3-positive tumors, have been inspected for potential 
Stat3 cognate elements, namely MMP-3, -7 and -9. All three promoters containe  Stat3-
binding sites (not shown).  
 
In spite of extensive research on Stat3, the mechanisms which trigger excessive Stat3 
activity in cancer are poorly understood. Unlike other signalling molecules, no naturally 
occurring genetic mutations or amplifications of Stat3 associated with oncogenesis have 
been identified so far (Burke et al., 2001). This indicates that persistent Stat3 activity is 
most probably due to dysregulated events upstream of Stat3 within the signalling 
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pathways, e.g., activation or mutation of physiological STAT activators such as the Janus 
kinases. Alternatively, Stat3 activation in cancer could result from over-expression of 
growth factors and their receptors or inhibition of negative regulators (Bromberg, 2002). 
Various recent findings, including those shown in this work, point to an important role of 
cytokines and growth factors secreted by tumor cells.  
In contrast to tumor cell lines originating from other tumors, all colon carcinoma cell lines 
employed in this study were negative for Stat3 activity in the absence of cytokine 
stimulation. Interestingly, they showed profound activity of Stat3 upon implantation into 
immunodeficient mice and xenograft tumor formation (Corvinus et al., 2004). Attempts to 
promote cancerous cell behavior by providing culture conditions favoring non-adhesive 
growth for the colon carcinoma model cell line HT-29 (thus, mimicking aspects of the 
tumor tissue situation) yielded evidence that Stat3 activation may be induced via autocrine 
stimulation in the tumor. These results are in line with those by Vécsey-Semjén et al. 
(2002) who demonstrated that low passage COGA-1 cells were non-invasive on Matrigel-
coated membranes, but were clearly tumorigenic in nude mice. Moreover, HT-29 and 
colon-38 colon carcinoma cells were clearly invasive and metastatic in vivo, but not in 
vitro (de Both et al., 1999). In both systems investigated (xenograft tumors and cells 
cultivated on the non-coated plastic surfaces), induction of Stat3 activity was paralleled by 
enhanced expression and activity of MMP-1. These findings are consistent with the results 
of Aparicio et al. (1999), who showed in vitro that rat colonic cancer cells did not express 
MMP-1; however, its expression was very high in ascitic fluids and solid tumors formed 
by these cells. In vitro, MMP inhibitor batimastat did not affect rat colon cancer cell 
proliferation, and slightly reduced cell invasion. However, in vivo, batimastat treatment 
totally prevented peritoneal carcinomatosis and liver metastasis development, and 
significantly prolonged survival. All these results support the possibility of an autocrine 
activation loop of Stat3 in CRC cells that is connected to the control of MMP-1 activity. 
Autocrine loops involving factors that trigger Jak/STAT pathways have been identified as 
crucial for malignant cell behavior in several tumor models. In breast carcinoma cells, a 
mechanism of autocrine-mediated Stat3 activation has been identified which correlates 
with cell proliferation (Li and Shaw, 2002). In brain tumors, Stat3 is considered to play a 
central role in autocrine activation of the Vascular Endothelial Growth Factor (VEGF) 
system (Schaefer et al., 2002). Various examples of IL-6-triggered autocrine stimulation of 
tumor cells have been published recently, such as acute myeloid leukemia cells (Schuringa 
et al., 2000), melanomas cells (Moretti et al., 1999), breast cancer (Knupfer et al., 2004), 
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esophageal carcinoma (Leu et al., 2003), head and neck squamous cell carcinoma 
(Sriuranpong et al., 2003), prostate cancer (Royuela et al., 2004) renal carcinoma (Angelo 
et al., 2002; Horiguchi et al., 2002), and also human cervical cancer (Wei et al., 2001). 
Surprisingly, this work revealed that none of the cytokines of the IL-6 family were over-
expressed in conditioned growth media with high Stat3 activating potency. Instead, up-
regulation of six chemokines (MCP-1, Ang, IP-10, IL-1α, MIP-1δ and MIP-3α) was found 
in supernatants of HT-29 cells grown in non-adhesive conditions. 
Considering the possible role of MCP-1 in autocrine Stat3 activation, a wealth of evidence 
suggests that MCP-1 may play an important role in tumor formation. In contrast to the 
majority of normal cells, many human and murine tumor cells are known to constitutively 
produce high levels of MCP-1, e.g., human glioblastoma (Huang et al., 2002), melanoma 
(Nesbit et al., 2001), ovarian cancer (Hefler et al., 1999), breast carcinoma and lung cancer 
(Wong et al., 1998). Additionally, clinical studies suggest that high expression of MCP-1 
is a significant indicator of early relapse of human breast cancer (Ueno et al., 2000). 
Moreover, MCP-1 expression may contribute to the highly malignant phenotype of murine 
mammary adenocarcinoma cells (Neumark et al., 1999) and is capable of inducing 
angiogenesis, a very critical aspect of tumor growth (Goede et al., 1999). Expression of 
MCP-1 is strongly associated with chronic inflammation, which may promote tumor 
development (de Boer et al., 2000). cDNA microarray technology revealed the association 
between the accumulation of MCP-1 and the development of drug resistance in ovarian 
cancer cells (Duan et al., 1999). Furthermore, Huang et al. (2002) showed that inhibition 
of MCP-1 in glioblastoma cells with anti-MCP-1 antibody reduced cell proliferation rates. 
Not surprisingly, MCP-1 promotes glioblastoma cell colony formation in soft agar. The 
authors also discuss an autocrine mechanism of MCP-1 activation in these cells. Very 
interestingly, the MCP-1 gene is reported to contain Stat-binding elements in promoter 
regions. AG 490, a Jak2 inhibitor, reduced induction of this gene, as well as nuclear factor 
binding activity and activation of Stat1 and -3 in gangliosides-treated microglia (Kim et 
al., 2002). MCP-1-induced tyrosine phosphorylation of cellular proteins involved the 
phosphorylation of non-receptor tyrosine kinases Lyn, Jak2, cytoskeletal binding protein 
paxillin and downstream transcription factors Stat-3 and Stat-5 (Mellado et al., 1998; 
Biswas and Sodhi, 2002). 
Human angiogenin is an excellent substrate for the adhesion of HT-29 human colon 
adenocarcinoma cells. These cells adhere more quickly to human angiogenin than to 
fibronectin, laminin, collagen I, or collagen IV (Soncin et al., 1994). Etoh et al. (2000) 
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examined the relationship between the mRNA expression of angiogenin and 
clinicopathological features in 65 patients with colorectal cancer. They found a significant 
difference in the vascular involvement, lymph node metastasis, liver metastasis, and 
advanced stage in patients with high expression of angiogenin compared to those with low 
expression. Immunohistochemical analysis revealed that angiogenin was predominantly 
expressed in colon cancer cells (Kwon et al., 2002). Interestingly, a non-cytotoxic 
neutralizing monoclonal antibody prevents the establishment of HT-29 human tumor 
xenografts in up to 65% of treated athymic mice, and also prevents the growth of 
androgen-independent human prostate cancer tumors in athymic mice in a statistically 
significant, dose-dependent manner (Olson et al., 1994; Vallee and Riordan, 1997; Olson 
et al., 2002).  
Furthermore, several studies have also shown that levels of MIP-3α mRNA and protein 
were rapidly up-regulated in TNF α- and IL-1-stimulated HT-29 and Caco-2 colorectal 
carcinoma cells, with kinetics similar to those seen for MCP-1 and IL-8 (e.g., Kwon et al., 
2002). 
It is highly important to identify the nature of the autocrine Stat3 activator in colon 
carcinoma cells. Ways of achieving this aim include treatment of cells with recombinant 
chemokines to confirm the positive effects, and the use of specific antagonists and 
inhibitory antibodies to block the Stat3 activating effect of cell culture medium from HT-
29 cells grown on the non-coated plastic surface of Petri dishes. 
Prognosis in patients with colorectal carcinoma has conventionally been determined using 
a staging system based on the extent of primary tumor and the presence or absence of 
metastasis, as in Dukes’ classification (Shiozawa et al., 2003). In the absence of curative 
surgical options for colonic cancers, chemotherapy is the primary method of treatment, 
albeit only a palliative one. This has prompted numerous investigations into better 
therapeutic strategies. 
Increased knowledge of the molecular mechanisms underlying cancer initiation and 
progression has led to the identification of signalling pathways that have gone awry in 
tumor cells, thus providing new molecular targets for therapeutic intervention in cancer. 
Fundamental basic research has contributed not only to the identification of particular 
oncogenes involved in cancer development but also to the delineation of whole signalling 
pathways. This knowledge of signalling pathways has proven to be of even broader benefit 
for the development of cancer drugs. Targeting of molecules embedded in such pathways, 
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but not identical with the causal oncogene, is especially applicable when the causal trigger 
is difficult to inhibit (Gibbs, 2000).  
In this context, this work contributes to promising developments put forward by others 
toward establishing the Stat3 signalling pathway as a valid molecular target for therapeutic 
intervention in a variety of human cancers (Bowman et al., 2000; Bromberg and Darnell, 
2000; Turkson and Jove, 2000; Song and Grandis, 2000). Inhibition of STAT signalling 
has repeatedly been demonstrated to result in growth inhibition and induction of apoptosis 
in tumor cells harboring constitutive activation of Stat3 ((Burke et al., 2001; Niu et al., 
2002; Real et al., 2002). Studies using normal mouse fibroblasts demonstrate that 
disrupting Stat3 signalling causes growth arrest but not apoptosis (Bowman et al., 2001), 
suggesting that blocking Stat3 signalling may not be excessively toxic. One possible 
explanation for the increased sensitivity of transformed cells to apoptosis compared to 
normal cells is that tumor cells may have become irreversibly dependent on STAT 
signalling for survival. The observed dependence of certain tumors but not normal cells on 
constitutive STAT activation for survival has wide implications for cancer therapy, 
offering the potential for preferential tumor cell killing. Since inhibition of STAT proteins 
is not necessarily toxic to normal cells, and even partial inhibition might be sufficient for 
successful treatment, STATs have become an attractive target for pharmaceutical research. 
It is also important to note that inactivation of STAT proteins might resensitize resistant 
cancers to apoptosis-inducing chemotherapeutic agents (Bowman et al., 2000). 
 
The role of MMPs in tumor invasion and angiogenesis has been well established. Based on 
rational design techniques, several MMP inhibitors have been synthesized, and their 
therapeutic effect examined. Unfortunately, several large-scale clinical trials of broad-
spectrum MMP inhibitors on malignant cancers failed or were suspended because of 
intolerable side effects, most likely due to blockage of MMP functions that are critical for 
normal physiological processes (Fletcher, 2000). Further understanding of the mechanism 
by which Stat3 activates MMP-1 gene transcription may help to identify new specific 
therapy strategies that are designed to block specific pathways, with subsequent inhibition 
of MMP synthesis. 
Currently, several means of blocking STAT activation are in development, such as receptor 
antagonists, tyrosine kinase inhibitors, STAT DNA binding blockers, STAT SH2 domain 
inhibitors, and naturally occurring inhibitors such as protein inhibitors of activated STATs 
(PIAS), decoy oligonucleotides, and STAT depletion (Reviewed in Ravandi et al., 2002). 
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Some “signal transduction inhibitors” that, among other effects, impair STAT signalling, 
have already entered the clinical phase. For example, STI571 ("Gleevec"; by Novartis) 
(Druker et al., 1996; Druker et al., 2001) blocks bcr-abl, v-abl, PDGFR and c-kit tyrosine 
kinase activities (Attoub et al., 2002; Scandura et al., 2002), all likely to affect STAT 
function. Inhibitors of Jak family kinases such as AG 490 block Stat3 activation and 
survival of human myeloma cells, breast, renal and prostate cancer cells (Meydan et al., 
1996; Horiguchi et al., 2002). Furthermore, Src family kinase inhibitors have been shown 
to block Stat3 activation and induce apoptosis of breast cancer cells (Garcia et al., 2001), 
also epidermal growth factor receptor (EGFR) inhibitors block Stat3 activation and 
survival of human renal carcinoma cells (Kedar et al., 2002).  
The development of more specific inhibitors of STAT signalling is being pursued 
extensively. This includes Stat3 anti-sense oligonucleotides, which block the growth and 
survival of squamous carcinoma cells of the head and neck (SCCHN) (Grandis et al., 2000; 
Leong et al., 2003), non-small lung cancer cells (Song et al., 2003), and prostate cancer 
cells (Barton et al., 2004). Protein inhibitors of constitutive Stat3 signalling have proven to 
be of great value in suppressing cancer cell growth in vitro and in vivo (Buettner et al., 
2002). Gene therapy of a mouse model of melanoma using the dominant-negative Stat3 
variant, Stat3-β, yielded inhibition of tumor growth and even tumor regression. Although 
only about 10–15% of the tumor cells were transfected in vivo, the Stat3-β induced anti-
tumor effect was associated with massive apoptosis of melanoma cells, indicative of a 
potent bystander effect. This bystander effect is mediated in part by the release of soluble 
factors that are capable of inducing apoptosis and cell cycle arrest of non-transfected tumor 
cells (Niu et al., 2001). In addition, recent studies indicate that constitutive Stat3 signalling 
induces VEGF expression and tumor angiogenesis, suggesting that suppression of 
angiogenesis may be part of the therapeutic efficacy of Stat3 inhibitors (e.g., Niu et al., 
2002; Wei et al., 2003). 
Taken together, the following strategies for targeting constitutive STAT signalling are 
under investigation: (a) development of receptor-ligand interaction antagonists, such as 
cytokine antagonists and receptor-neutralizing antibodies; (b) alteration of STAT 
interacting proteins, such as the PIAS and suppressors of cytokine signaling (SOCS) 
family members; (c) inhibition of STAT-activating serine kinases; (d) activation of STAT-
specific phosphatases; (e) targeting of STAT-regulated genes involved in malignant 
progression; and (f) development of small molecule inhibitors that interfere with STAT 
dimerization and/or DNA binding (Reviewed by Buettner et al., 2002). A wealth of 
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findings in recent years, some of which are mentioned here, make the therapeutic potential 
of STAT factors in cancer appear very promising. 
It is important to further investigate the possible prognostic significance of aberrant STAT 
activity in cancer. It has been shown in some studies that Stat3 activation is significantly 
associated with poor prognosis. For example, increased levels of phosphorylated Stat3 in 
HNSCC cells (Masuda et al., 2002) and in acute myeloid leukemia blasts (Benekli et al., 
2002) are associated with lower survival rates. In addition, a significant association of high 
levels of p-Stat3 with metastasis was observed in renal carcinoma cells (Horiguchi et al., 
2002). The number of CRC patients included in this work is unfortunately not sufficient 
for statistically significant correlation of Stat3 activation with clinical data und requires 
extension in the future.  
Interestingly, activation of Stat1 in breast cancer is a favorable prognostic marker 
(Widschwendter et al., 2002). It has also been reported that following radiotherapy, 
patients with nasopharyngeal carcinoma with constitutive Stat5 activation, or activation of 
both Stat3 and Stat5, had better disease-free survival and overall survival than those 
without activated Stat5 (Hsiao et al., 2003). 
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 8. CONCLUSION 
 
The results of this work suggest that aberrantly activated Stat3 contributes to malignancy 
in colorectal cancer. It enhances parameters of cell transformation such as proliferation, 
anchorahe-independent growth and invasiveness. The expression of MMP-1, a proteolytic 
enzyme with importance for the invasive properties of colorectal tumors, relies upon Stat3 
activation. The mechanism of Stat3 activation within colorectal tumors probably includes 
an autocrine stimulation loop. Stat3 is a potentially interesting both as a marker and a 
therapeutical target in colorectal carcinoma.   
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